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Introduction: As with any transplantation (Tx) procedure, uterus Tx is 
associated with risky donor surgery and adverse side-effects from 
immunosuppression. With the aim to bypass these risks, this thesis 
investigated uterus tissue engineering strategies and the potential to 
develop a patient-specific uterus graft to replace the need for donor 
surgery and immunosuppression. A translational approach for uterus 
scaffold production through a process called decellularization (DC) is 
addressed using the rat and the sheep animal model. The 
immunological events following engraftment of rat uterus scaffolds was 
also evaluated. The thesis also assessed cellular reconstruction 
techniques and perfusion bioreactor protocols that can be useful to 
recellularize whole sheep uterus scaffolds for future uterus Tx studies.  
Methods: The immune response towards three different rat uterus 
scaffold types were evaluated after transplantation by quantifying 
infiltrating leucocytes and the expression of pro-inflammatory cytokines. 
Additionally, three novel whole sheep uterus scaffolds were produced 
by DC and the scaffold composition, bioactivity, mechanical strength 
and ability to support seeded stem cells were analyzed. Technique 
optimization for a perfusion bioreactor was also conducted using normal 
sheep uterus and a specialized perfusion medium.  
Results and conclusions: In Paper I, we deciphered DC protocol-
dependent differences in the immune response following engraftment. 
A mild, yet effective DC protocol resulted in an immune-inert scaffold 
type. In Paper II-III, we developed three promising extracellular matrix-
derived bioactive sheep uterus scaffolds that after an enzymatic pre-
conditioning were able to support wide-spread cell attachment and 
migration during recellularization. In Paper IV, we were able to maintain 
normal sheep uterus ex-vivo for 48 hours using a custom made culture 
medium and a perfusion bioreactor. These parameters should facilitate 
future whole sheep uterus tissue engineering experiments so that a 
patient-specific tissue engineered uterus can be made to replace a 
donor in a uterus Tx setting.  
 
 
SAMMANFATTNING PÅ SVENSKA 
Introduktion: I likhet med andra organtransplantationer är 
livmoderstransplantation förknippat med risker under donationskirurgin 
samt med biverkningar från den immunosuppressiva behandlingen. 
Med avsikt att försöka kringgå dessa risker undersöker denna 
avhandling möjliga strategier som kan leda till framställningen av en 
konstgjord livmoder som är patient-specifikt och som består av ett 
biomaterial som fyllts med patientens egna stamceller. På ett 
translationellt forskningssätt beskriver denna avhandling hur ett 
livmodersbiomaterial kan framställas för djurstudier på råtta och får. 
Biomaterialens förmåga att undvika en immunförsvarsreaktion efter 
transplantation undersöks också. Dessutom så utvärderas olika 
stamcellsappliceringsmetoder och olika perfusionsbioreaktorer som 
kan bli gynnsamma för framtida transplantationsstudier.  
Metoder: Immunreaktionen utvärderades genom kvantifiering av 
infiltrerade immunceller efter att tre olika råttlivmodersbiomaterial 
transplanterats. Genuttrycksanalyser på proinflammatoriska cytokiner 
gjordes också. Dessutom framställdes tre nya fårlivmodersbiomaterial. 
Dess biologiska sammansättning och egenskaper analyserades i 
detalj, inklusive dess förmåga att främja stamcellstillväxt. Dessutom 
utvärderades ett speciellt framtaget perfusionsmedium för att hålla en 
fårlivmoder vid liv i en bioreaktor. 
Resultat och slutsatser: I Delarbete I så upptäcktes biomaterials-
specifika skillnader på aktiveringen av immunförsvaret efter 
transplantation. Ett milt men effektivt framställningsprotokoll 
producerade biomaterial som tolererades av värddjuret. I Delarbete II-
III så tillverkades tre lovande fårlivmodersbiomaterial som efter en 
enzymbehandling kunde stimulera en mycket effektiv 
stamcellsuppbyggnad. I Delarbete IV så visades att en fårlivmoder 
kunde hållas vid liv i 48 timmar i en bioreaktor med hjälp av ett eget-
utvecklat perfusionsmedium. Dessa bioreaktorparametrar gynnar 
fortsatta försök med mål att framställa en komplett konstgjord livmoder 
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INTRODUCTION 
Becoming a parent is one of the most prevalent and awaited desires in 
adulthood that unites all ethnic, cultural, linguistic and economic groups. 
However, the dream of having a child does not come true for some 
couples, which can cause substantial negative psychological effects for 
the affected persons.1 Infertility is a growing public health concern in 
most parts of the world. While some infertile couples become parents 
with the aid of assisted reproductive technologies (ART) and others by 
adoption, there are still a significant number of couples who remain 
childless in spite of their strong wish for parenthood. 
Nowadays, tissue engineering (TE) of organs is not exclusively 
prescribed for life-threatening conditions such as diseases of the heart, 
lung, liver, kidney or bone, but has now been explored as treatment 
options for quality of life enhancing measures, e.g. the hand or the 
uterus. Although clinical trials of tissue engineered grafts have been 
performed, it is still considered an experimental procedure. Progress is 
yet to be made in optimizing protocols, addressing safety & ethical 
concerns before advancing to future clinical trials. 
 
Infertility 
Infertility, according to the World Health Organization’s (WHO) 
International Classification of Diseases 11th revision is described as “A 
disease of the reproductive system defined by the failure to achieve a 
clinical pregnancy after twelve months or more of regular unprotected 
sexual intercourse”.2,3 For women below 29 years of age, 79% of the 
pregnancies occur during the first six menstrual cycles of unprotected 
intercourse while for women of 29 years of age or above, 74% become 
pregnant.4 Overall, infertility affects between 10% and 15% of couples 
of reproductive age worldwide,5 which totals the amount to affect more 
than 72.4 million couples.6 There are two main circumstances leading 
to infertility: (i) primary infertility caused by the absence of conception 
and (ii) secondary infertility which affect couples that have had earlier 
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pregnancies but are unable to get pregnant a second time. Both of 
these infertility causes can be further divided into: “female factor”, “male 
factor”, “combined factor”, “unexplained infertility” and “other causes” 
which correspond to 30%, 30%, 10%, 25% and 5% respectively. In spite 
of this fact, it is challenging to precisely establish the singular 
explanation for these aspects.7,8 The causes for male factor infertility 
are usually due to poor semen quantity and/or quality, or prevention of 
ejaculation due to an obstruction of the seminal duct. It was also 
observed that sperm quality in males have declined by up to 50% in the 
last 50 years in the industrial world.9 Regarding female factor infertility, 
the majority of the cases can be attributed to ovulatory dysfunctions, 
premenstrual syndrome, abnormal bleeding or atypical cycle length as 
well as several uterine factors.10 The WHO has pinpointed frequent 
causes for female infertility (excluding ovarian factors) as tubal 
abnormalities (26%), hyperprolactinemia (4%), endometriosis (4%) and 
genital tract diseases (4%) that e.g. negatively affect implantation.3,11 
 
Uterine factor infertility 
Absolute uterine factor infertility (AUFI) is a condition where women 
cannot become pregnant due to an absent or a non-functioning uterus. 
No current standard ART may cure this infertility condition. Overall, the 
estimated amount of women with a uterine factor infertility is around 3-
5% of the total women suffering from infertility12 which adds up to 
around 4 500 fertile aged women just in the Nordic countries.13 
Of all the uterine factor infertility conditions, a majority are caused by 
an acquired injury to the uterus. Myoma for example, is a common 
benign pathology that affects 21% to 26% of all women. More 
specifically, around 10% of women aged 33-40 are affected, but the 
condition becomes more prevalent with increasing age.14 The cause-
specific infertility among women affected with myoma is around 40%.15 
The current treatment options for this is either corrective surgery 
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(myomectomy) for women who are yet to have a family, or 
hysterectomy for women who already had children.15 
Figure 1. A diagrammatic illustration types of uterine factor infertility. 
Another reason for AUFI are intrauterine adhesions (Asherman’s 
syndrome) that lead to inability to achieve pregnancy or repetitive loss 
of pregnancy. These luminal adhesions are often the secondary 
consequence from primary intrauterine infections, genital tuberculosis 
or from previous surgical abortions. Untreated intrauterine adhesions 
can lead to an increase in infertility rates classified as AUFI.16 Uterine 
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adhesions can be treated by hysteroscopic lysis of the adhesions, and 
in most cases, the shape and size of the uterine cavity can be restored. 
Nonetheless, close to two-thirds of women with serious adhesion 
problems do not have their fertility restored even after surgery.17 
Sudden peripartal infertility is also a condition of AUFI. This is caused 
by a hysterectomy that was performed immediately or within 24 hours 
(h) after delivery as a lifesaving treatment for the mother due to e.g. 
uterine rupture, atonic bleeding or an abnormally invasive placentation. 
This is a condition that affects 3-4 per 10 000 women in the Nordic 
countries.18 
Another cause of AUFI is cervical cancer, which is the second most 
common type of cancer that affects women worldwide.19 50% of the 
diagnosed women with cervical cancer are under 40 years of age,20 and 
a significant number of patients are under 30.21 There is an estimate 
that around half of the women who are diagnosed with cervical cancer 
that are below 40 years of age undergo fertility-sparring surgical 
interventions by the trachelectomy procedure, where the uterus is 
exempted during surgery while the cervix is resected.22 The remaining 
women who are not eligible for the abovementioned treatment usually 
undergo hysterectomy, causing AUFI.23 
Another cause of AUFI is due to congenital malformations that 
represents around 7% of women with AUFI.24 This condition causes 
uterus abnormalities as a result of a failed absorption of the partition 
between the fused Müllerian ducts or a developmental abnormality that 
resulted in a bicornuate uterus (Figure 1). The abovementioned two 
syndromes could be associated with almost normal fertility or cured by 
surgery. Other types of congenital uterus abnormalities includes 
didelphic uterus or unicornuation. These cannot be cured by surgery 
and represents about 20% of the total cases of congenital uterus 
abnormalities.25 However, there is also a less common but more severe 
abnormality classified as the Mayer-Rokitansky-Küster-Hauser 
syndrome which affects around 1 in 4500 women. These women have 
a complete absence of a uterus from birth, or may only have an under-
developed uterus.26 
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Treatments for infertility 
Treatments for male infertility 
For men, there are a few treatments that alleviate some types of 
infertility. The most common problems are reduced sperm quality and 
issues with sperm motility. These problems can in most cases be 
overcome by intracytoplasmic sperm injection.27 Other examples of 
fertility treatments may include testosterone supplementation to men 
who have low androgen levels,28 or other medications to prevent 
erectile dysfunction caused by hypertension/angina pectoris.29 Surgery 
is a solution for men who suffer from a blockage in vas deferens.30 
There is also a method to isolate sperm directly from the testicular 
tissue using microdissection testicular sperm extraction/aspiration that 
has resulted in successful outcomes in the clinic.31 More recent 
advancements, but so far only in animal models, have shown that it is 
possible to produce artificial male (and female) gametes from induced 
pluripotent stem cells which also led to successful livebirths of animal 
offspring. Although these techniques are still in the experimental phase, 
this strategy may reach the clinic in the future.32 
 
Treatments for female infertility 
There are many treatment options for female infertility. Women who 
suffer from a mild subfertility with ovulation disorders may be treated 
with hormone supplements to improve ovarian stimulation.33 Surgery is 
an option for women diagnosed with endometriosis, adenomyosis, 
uterine adhesions or blocked Fallopian tubes.33,34 
The most significant advancements in infertility treatments throughout 
the years are the ART. Intrauterine insemination is one of the oldest 
method where the world’s first documented procedure was performed 
in the UK in 1884. This method involves the placement of semen into 
the uterus of an ovulating woman. Although controversial in its early 
days, this strategy is now widely used to help couples conceive.35 In-
vitro fertilization (IVF) was a revolutionary treatment that was developed 
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and successfully performed by Robert Edwards in the UK in 1978 for 
which he was awarded the Nobel Prize in Physiology and Medicine in 
2010. This method involves the aspiration of mature oocytes from 
follicles of the ovaries, and fertilizing it in-vitro using semen. The 
fertilized oocytes are then normally cultured for 3-5 days in-vitro prior to 
embryo transfer into the uterine cavity where it ultimately implants and 
continues to develop into a normal fetus. This method may benefit both 
infertile men and women as it overcomes problems related to reduced 
sperm quality/motility, and women with ovulatory problems or fallopian 
tube obstruction, including solving some unexplained infertility 
conditions.36  
With all these advancements being revolutionary, there are still some 
women who cannot become fertile. These women may suffer from 
uterus-related infertility conditions such as AUFI, or have some type of 




Figure 2. Translational process of uterus transplantation from the mouse, rat, 
rabbit, pig, sheep, non-human primates and finally, the human. 
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Early preclinical uterus transplantation studies 
As some infertility causes (e.g. AUFI) could not be overcome by other 
available approaches, uterus transplantation (UTx) has been explored 
as a means to treat female infertility. Initial experiments on UTx was 
performed in 1927 on dogs where avascular grafts were placed in the 
omentum leading to a reasonable success based on the uteri still being 
viable after eight months.37 This study was followed up in 1960s by a 
study where the UTx was conducted with vascular anastomoses in 14 
dogs. Five dogs survived the transplant procedure after the 
administration of azathioprine as immunosuppression.38 Around the 
same time, there was also a study that reported successful pregnancy 
after vascular anastomosed autologous UTx procedures in eighteen 
dogs that resulted in the delivery of two litters with three and nine pups, 
respectively.39 In the 1970s, non-vascular anastomosed UTx in the 
omentum was performed in non-human primates (macaque) in 
autogenic and allogenic conditions. Neo-angiogenesis was observed, 
followed by full rejection at day 14 in the allografted group.40 
More recent small animal models of UTx 
The breakthrough of IVF in the late 1970s had lead to a decreased 
interest for UTx. However, in the early 2000s, with modern 
improvements in the fields of surgical techniques and 
immunosuppressive therapies, Prof. Mats Brännström initiated a 
research program on UTx using vascular anastomosis protocols in 
experimental animals. Initially, the uterus was explanted and 
heterotopically transplanted into syngeneic mice to evaluate surgery 
procedures in rodent models41 with successful pregnancies reported 
shortly after.42 Additional studies evaluated the function and viability of 
the uterus after engraftment following different cold ischemia protocols 
where the authors showed that the rodent uterus can tolerate cold 
ischemia times of up to 24h and still be functional.43 
Tissue engineering for novel female infertility treatments 
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The initial rat UTx model was first reported in 2008.44 This was a 
heterotopic UTx model where the syngeneic graft was anastomosed to 
the aorta and vena cava while the native uterus was left untouched 
(Figure 3). This was followed up by an orthotopic UTx that resulted in 
successful pregnancy after spontaneous mating.45 This was followed by 
the first pregnancy and live offspring in an allogeneic model using 
tacrolimus as immunosuppression. The pregnancy went to term and the 
rat pups developed normally.46 The effect of warm ischemia was also 
studied where longer warm ischemia times more than 4h detrimentally 
affected the viability of the uterus after transplantation.47 
Figure 3. Figure used with permission from the publisher and authors.44 
Photographs of the grafted uterus transplanted heterotopically on a) day 1, b) 
day 21 and c) end to side anastomosed blood vessels in the rat. 
Large animal models 
These successful UTx protocols for rodents were then translated and 
evaluated on larger animal models. The first autologous UTx reported 
on pigs was conducted in 2005 and showed that there were problems 
after engraftment due to a gradual formation of vascular thrombosis.48 
Another study on autologous pig UTx was performed where the uterus 
had been preserved with Ringer’s acetate solution during the cold 
ischemia time before being and re-transplanted. However, The results 
from this study were slightly better than the earlier studies on the pig, 
with successful blood reperfusion seen in 4 out of 19 animals.49 An 
allogeneic UTx study was then performed in the smaller mini-pig model 
with the administration of tacrolimus and cyclosporine as 
immunosuppression. This study showed that the grafted uterus was 
viable in half of the transplanted pigs one year after UTx.50 
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The porcine animal model is often used in development and training of 
surgery, and is considered the best large preclinical animal model after 
non-human primates. However, for female infertility studies, the sheep 
is considered the best animal model since the size of the uterus and the 
vascular anatomy are more comparable to the human uterus. The first 
autologous sheep UTx was performed in 2008 where successful blood 
reperfusion was observed in 5 out of 7 transplanted animals.51 The 
surgical technique was then modified where the uterus was 
transplanted with one uterus horn along with the ovary. The outcome of 
the study had favorable outcomes with a 50% animal survival rate, and 
60% of the surviving animals became pregnant after natural mating.52 
Prof. Brännström’s team continued to look into various aspects of UTx 
protocols and also investigated the effects of warm and cold ischemia 
injury-related damage to the sheep uterus. These studies concluded 
that the sheep uterus was robust and could tolerate at least one hour of 
warm ischemia.53 The first allogeneic sheep UTx was performed on 12 
sheep where cyclosporine was used for immunosuppression. Five of 
the animals had embryo transfer and three pregnancies were reported 
leading to one livebirth from a cesarean section.54 However, another 
group reported some organ rejection and necrosis problems after an 
orthotopic allogeneic UTx in the sheep, even after immunosuppression. 
55 
Following the developed surgery techniques on the sheep and the pig 
animal models, further UTx investigation was conducted in non-human 
primates, including on macaques and baboons due to their near 
resemblance to the human uterus in anatomy and physiology. The first 
UTx on a baboon model was performed in Saudi Arabia with an 
autologous orthotopic UTx that demonstrated positive results in graft 
survival after 6-12 weeks.56 Prof. Brännströms group also reported 
successful autologous UTx in baboons and assessed the long-term 
results. In brief, five of the nine animals survived the UTx, of which two 
animals resumed menstruation.57 The same group reported an 
allogenic UTx in baboons where all the recipient animals showed signs 
of mild rejection. There was no kidney damage despite the animals 
having high tacrolimus levels in the blood. Nevertheless, the authors 
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suggested the need to optimize the immunosuppression regimen.58 A 
Japanese team then reported UTx on two macaques where one animal 
died due to renal failure, while the other animal was healthy and 
resumed menstruation post-surgery.59 The same group was successful 
with an imaging technique to evaluate blood flow following 
transplantation using indocyanine green. They suggested that a 
unilateral anastomosis of one uterine artery and one uterine vein 
provided sufficient blood to the uterus grafts following UTx.60 
Human studies 
The first clinical uterus transplant was performed in the year 2000 in 
Saudi Arabia with little prior UTx research or any significant preparation 
except for the above mentioned short-term baboon UTx. A group of 
surgeons decided to try the UTx procedure as a fertility treatment for a 
26 year old hysterectomized woman who received the uterus of a 46 
year old woman undergoing hysterectomy due to benign ovarian cysts. 
After blood and tissue typing, the UTx was performed with no major 
complications initially. However after three months, the graft showed 
necrosis with thrombosed vessels that lead to the removal of the graft.56 
The second human UTx case was then conducted by a group in Turkey. 
Similarly to the Saudi Arabian case, no previous UTx research or 
training had been conducted by the group prior to the human trial. The 
patient was a woman diagnosed with uterus aplasia and the donor was 
a young, nulliparous multiorgan donor. The patient had menarche and 
regular menstrual cycles after the transplantation surgery.61 Multiple 
embryo transfers were attempted, and clinical pregnancy achieved 
which suggested that embryo implantation can take place in a 
transplanted uterus. However, no live birth from this patient has been 
reported.62 
The first successful UTx with a livebirth was performed at Sahlgrenska 
University Hospital by a surgical team lead by Prof. Brännström after 
more than a decade of translational research.63 This has since been 
followed up with multiple subsequent livebirths from other patients 
operated by the same team with improved operating protocols.64-66 To 
date, there are 11 babies born in the Swedish clinical trials and there 
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are now multiple additional livebirths reported from around the world.67-
72 UTx has thus been proven to be a novel fertility treatment for the 
earlier believed “untreatable” condition of AUFI. However, the 
procedure is still considered an experimental treatment, and protocols 
are continuously being optimized and improved, e.g. regarding the 
donor source (live or deceased donor),63,69,70,73 the use of robotic 
surgery to reduce operating time and blood loss,66,74-76 positioning of the 
vascular anastomosis77,78 and organ preservation methods.79-81  
 
Risks with uterus transplantation 
In general, there is a shortage of organ donors all around the world.82  
This also implies for UTx since the strict donor criteria for UTx limit the 
availability of donor uteri, even when using deceased donors. 
Furthermore, it is common that vital organs such as the liver, lung, 
kidney or the heart are the first organs to be explanted to limit organ 
damage associated with the warm ischemia time. The uterus would not 
be considered a high priority organ as it is not essential for survival. 
Therefore, a deceased donor uterus may have experienced a longer 
warm ischemia than other organs that may adversely affect the 
outcome after transplantation. Thus far, most of the current successful 
UTx cases that resulted in livebirth came from a living donor. These 
operations are easier to plan logistically, and the donor uterus can be 
thoroughly examined prior to the donor surgery. However, the donor 
surgery is a risky procedure since it involves operating deep into the 
pelvis as the uterus needs to be isolated with long intact blood vessels, 
which are in anatomical proximity to the uterus, in order to facilitate a 
vascular anastomosis upon engraftment and with undistributed ureteric 
function in the donor.83 The recipient further risks significant adverse 
side-effects from the carefully curated immunosuppression regimen to 
prevent organ rejection, including infections, renal failure or embryo 
implantation failure.84-86 The last point is important to consider since the 
whole reason for UTx is to restore fertility. Excluding donor or recipient 
death, or risks related to unintentional surgery inflicted injuries to other 
organs such as the ureter or the colon, the worst case scenario is the 
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possibility of organ rejection. Although immunosuppression has 
advanced to a great extent, the risk of organ rejection is still significant. 
A part of the aforementioned risks could potentially be overcome with a 




An abridged definition of TE is the construction of a viable organ in a 
lab that can be used for transplantation to restore and/or improve the 
function of a damaged organ in the recipient. This may be done with a 
3D scaffold along with cells and growth factors (GFs) that facilitate in-
vivo remodulation and function post transplantation.87 In the clinic, TE 
constructs have been used in vascular grafts,88 bone89 and skin 
regeneration applications.90 Additional TE solutions have been used for 
urethra,91 breast92 and trachea.93 However, to achieve proper TE for 
more complex organs is challenging. Therefore, much preclinical 
research is focused on the construction of TE organs suitable to replace 
an organ donor in a transplantation setting. If successful, such a feat 
would revolutionize the organ source for transplantation as an organ or 
a tissue could be constructed from an immune-inert scaffold and the 
patient’s own cells, thereby eliminating immunological barriers such as 
human leukocyte antigen compatibility and immunological donor-
recipient matching. This may be used for essential and elective 
surgeries both of which would improve quality of life of the patient. 
As summarized briefly below, there are a number of different scaffolds 
that may be appropriate to use for TE applications, and they all have 
their respective pros and cons. However, all scaffold types should 
optimally be immunologically inert, not contain any donor nuclear 
material and facilitate regeneration. 
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Polymer scaffolds 
Polymer is derived from the Greek words “poly” and “mer” meaning 
many and parts, respectively. Scaffolds made of polymers can be either 
natural or synthetic. Natural polymeric scaffolds are derived from a 
natural source where the components can be found in the body and 
could thus be absorbed after implantation. Examples of natural polymer 
scaffolds include those made of collagen, hyaluronate, gelatin, 
chitosan, fibrin and silk, among many others.94 The major advantages 
of these scaffolds are that they are biocompatible, biodegradable and 
have shown to be able to facilitate cell adhesion and migration, while 
the disadvantages are batch variation and limited mechanical 
properties.95 Synthetic polymeric scaffolds are made of either fully 
synthetic monomers (e.g. poly-caprolactone and poly-dioxanone), or 
semi-synthetic sources (such as poly-lactic acid, poly-glycolic acid or 
poly-glactin, among others).94 The advantages with these types of 
biomaterials are reproducible batches, good mechanical scaffold 
properties and sterility. However, the disadvantages with these types of 
biomaterials are that they can cause an immune response when the 
polymers are broken down into monomers.96 There is a recently 
published report of a polymer based uterus scaffolds that resulted in 
livebirths in rabbits,97 further described in detail later in this thesis. 
 
Porous scaffolds 
Porous scaffolds may be derived from a natural source (i.e. from marine 
resources such as Porifera sponges)98,99 or synthetic sources such as 
hydroxyapatite composites, gore-tex or dacron among others.100 The 
advantage using these scaffolds is the absence of an inflammatory 
response post in-vivo engraftment. 
 
Hydrogel scaffolds 
Hydrogels are gels made of large cross-linked molecules that can 
absorb a lot of water. On account of their hydrophilic nature, they are 
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somewhat similar to native organs. Hydrogels can be produced either 
from digested organ matrices or from semi-synthetic polymers like poly-
ethylene glycol that has biodegradable functional groups. One 
interesting application for hydrogels is its use for 3D bio-printing of 
organs using a biocompatible matrix along with cells. This is yet to be 
further optimized for smaller constructs, but has been used for tissues 
like bone and cartilage.101,102 
 
Extracellular matrix derived scaffolds 
Extracellular matrix (ECM) derived scaffolds are generated from tissues 
or organs after the successful removal of cells in a process named 
decellularization (DC). To the best of my knowledge, the first ever tissue 
engineered ECM scaffold was performed in 1977 where a decalcified 
bone was used as graft after it had been seeded with stem cells. The 
construct was shown to stimulate the repair of a defective knee joint in 
a rabbit model.103 Since then, TE ideas, protocols and technologies 
have improved significantly. Currently, TE studies using decellularized 
tissue as scaffolds have been performed in a multitude of organs and 
in a great variety of animal models, including studies on the heart,104 
lung,105 urethra,106 liver107,108 and more recently the uterus.109-119 The 
advantage of using the ECM as a natural scaffold is that it is composed 
of the same building blocks of the organ of interest, and it can give 
structural support and provide essential GFs for the migration and 
proliferation of cells during remodeling. 
Components of the extracellular matrix 
The ECM is comprised of a myriad of components, all of which are very 
important for the natively present cells. The most prevalent and well-
studied components of the ECM are collagen, elastin, sulfated 
glycosaminoglycans (GAGs), fibronectin and laminin which are 
summarized below. 
Collagen is a protein that makes up around 85% of the ECM. There 
are around 28 types of collagen, all of which give structure, strength 
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and shape to the tissue. Collagen type I is the most abundant collagen 
in the human body and is principally located in bones, tendons and skin 
but is also a major component in other tissues.120 The uterus 
predominantly consists of collagen types I, III, IV and V.121 More 
specifically, collagen types I and V are predominantly distributed around 
cells while type III are organized around cell bundles.122 
Elastin is an important protein that is responsible for elasticity, 
contractibility and load bearing properties and co-exists with collagen in 
all organs. Naturally, it is important in the uterus for its ability to expand 
during pregnancy. However, it is also responsible for signaling, giving 
mechanical stability and organization of the ECM structure.123 The 
distribution of elastin shows variations in different locations of the uterus 
where only small amounts of elastin can be found in the inner smooth 
muscle layer close to the endometrium. However, there is a gradient 
increase of elastin towards the outer myometrium with a significant 
distribution of elastin at the serosal boundary. There is also an 
increasing gradient of elastin in the lower part of the uterus especially 
in the uterine cervix.124 
The GAGs are complex carbohydrates with the addition of an amino 
group that are negatively charged. The viscosity and hydrophilicity of 
GAGs make them retain water and will then provide an effective storage 
place for GFs, chemokines and cytokines. They are present on both the 
ECM structures and the cell surfaces.125 The uterus is rich in GAGs 
where the endometrium has a predominance of chondroitin sulfate 
along with smaller amounts of dermatan sulfate and heparan sulfate, 
while the muscular myometrium has a high level of hyaluronic acid.126 
Fibronectin comes second, after collagen, in the abundance of specific 
ECM components in the body. A soluble form of fibronectin is found in 
the circulatory system and an insoluble form is found in the ECM. The 
dimeric form of the protein can bind to other ECM components such as 
collagen, heparan, fibrin among others.127 In the uterus, it is well 
distributed everywhere, but with the majority found mainly around cell 
bundles. Fibronectin also plays an important role in pregnancy where it 
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binds to cleaved collagen during pregnancy and is a key factor in 
collagen removal during the remodeling after pregnancy.122  
Laminin is a basement membrane glycoprotein that has 11 
recognizable molecular chains, found as alpha, beta and gamma 
subunits. Laminin has an affinity towards collagen type IV and heparan 
sulfate. It is essential for cell adhesion, migration and proliferation while 
also playing an important role in cell signaling.128 The uterus has, in 
relation to other organs, a high amount of laminin, especially in the 




The DC is the process of removing cells and cellular material (including 
nuclear material) from organs and tissues to create ECM derived 
scaffolds. There are a number of different methods to be used for this 
procedure. Since any DC process not only remove cellular components, 
but also results in the damage of the ECM structure and its mechanical 
properties, it is important to find a fine balance between effective 
removal of donor cellular material while retaining the important ECM 
components. The choice of the DC protocol employed depends 
completely on the type of tissue, its cellularity, thickness and 
mechanical properties.130 There are broadly two important factors that 
impact the DC process: physical and chemical factors. 
 
Physical factors 
Temperature is useful since freeze-thaw cycles disrupt the cell 
membranes in the tissue. This is often followed up with additional other 
methods for DC, and thereby enhancing the removal of cellular 
components. Temperature is also something to be considered while 
using detergents or enzymes as the efficacy of these strategies is 
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temperature dependent. Like every process, the free-thaw cycles can 
also irreversibly damage the ultrastructure of the DC tissue.131,132  
Agitation is the method where a DC reagent is in constant contact with 
the tissue during brisk stirring. The DC reagents penetrates the tissue 
through passive diffusion, thereby disrupting the cell membranes and 
dislodging them from the ECM. This method is often deployed for non-
vascular tissues like cartilage or bone, or pieces of soft tissue.133 
Perfusion is a method when a DC reagent is forced through the intact 
vasculature of the whole organ. It is an effective method for soft organs 
with vascular pedicles that can be cannulated, since the blood vessels 
reach the inner most parts of the tissue where, for example, DC 
protocols using passive diffusion cannot be reached. The advantage 
with this method is the effective removal of cells using lesser 
concentration of detergents or a reduced exposure time to DC reagents. 
This consequently reduces the ECM damage. Furthermore, the created 
ECM scaffold after a perfusion-based DC protocol also have an intact 
whole organ structure with remaining conduits of the vasculature. 
These conduits can be beneficial for cellular reconstruction 
experiments, and used in future vascular anastomoses protocols for 
transplantation studies in-vivo.104,134  
Ultra sonication is the use of ultrasound that causes physical vibration 
of the tissues. It is especially useful for DC of robust or dense tissues 
where the cells are dislodged from the ECM through the use of just 
mechanical force. The tissues are usually immersed in cold buffers in 
order to reduce heat from the sonication process that could 
inadvertently damage the ECM.135 
 
Chemical factors 
pH dependent solutions such as acids and alkalis act as DC reagents 
by lysing the cells due to the solubilization of the lipid layer and parts of 
the cytoplasm. The most commonly used acids include peracetic acid 
which is also widely used as a sterilization agent of ECM derived 
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scaffolds. A commonly used alkali includes sodium hydroxide. Although 
these reagents are efficient, this method for DC is known to significantly 
damage the structural ECM components, in particular collagen, GAGs 
and GFs.136 
Tonicity is the osmotic pressure gradient between two liquids 
separated through a semipermeable membrane which in the case of 
DC represents the cell wall. A hypertonic solution (e.g. salt water) has 
higher salt concentration than the cell, thereby making the cell shrink. 
Alternatively, a hypotonic solution (e.g. deionized water) has lesser salt 
concentration than the cell, and thereby water is forced into the cell 
through osmosis and causing it to swell and ultimately burst. Hence, 
tonicity is an effective DC strategy.135,137 
Solvents include the primary substance in which the actual DC reagent 
is dissolved in. The most widely used is deionized water. However, 
there are organic solvents e.g. alcohols or tri-n-butyl phosphate that 
effectively dissolve lipid-lipid or protein-protein bonds respectively. High 
polar solvents such as dimethyl sulfoxide (DMSO) may be effective DC 
reagents when interchanged with a hypotonic solutions since the 
osmotic shocks will disrupt cellular membranes.138 
Detergents are surfactants that have both hydrophilic and hydrophobic 
groups that influence the tissues during DC, depending on what 
detergent type and its concentration. Ionic detergents such as sodium 
dodecyl sulfate (SDS) and sodium deoxycholate (SDC) are effective 
and popular DC detergents since they break protein-protein bonds and 
can thereby effectively solubilize the cell-ECM bonds and cell-cell 
bonds.139-141 Non-ionic detergents (e.g. Triton X-100) are milder than 
ionic detergents in regards to the damage inflicted on the ECM during 
the DC process but may require longer exposure times to establish an 
effective DC of the tissue. Non-ionic detergents act by breaking protein-
lipid and lipid-lipid bonds.142 Zwitterionic detergents (e.g. CHAPS) have 
the properties of both ionic and non-ionic detergents and when used for 
DC can maintain the structural ECM integrity well. However, it tends to 
leave an abundance of cytoplasmic remnants in the tissue, and these 
remnants can be detrimental to the scaffold application.134,143 
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Enzymes are biological catalysts that facilitate chemical reactions. The 
enzymes used for DC are predominantly serine proteases and 
nucleases. Trypsin is the most used protease for removal of cells and 
acts by cleaving the bonds on arginine and lysine amino acids. This 
facilitates the removal of cell-ECM bonds while also disrupting some of 
the ECM protein structures.144 Nucleases such as deoxyribonuclease 
(DNase) cleave oligonucleotides thereby breaking down 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) strands to 
smaller fragments, which then could be washed away with another DC 
reagent or solvent.144,145 
Chelating agents (e.g. ethylenediaminetetraacetic acid) bind to metal 
ions such as calcium and magnesium and can thereby disrupt cell-ECM 
bonds. It can also be used for protease-rich tissues (i.e. pancreas) to 
inhibit the enzymes thereby reducing tissue damage.146,147 
 
Evaluation of decellularization 
Ideally, successful DC is achieved when all the cells, with their 
membranes and organelles as well as the nuclear material have been 
removed, while as much as the ECM is preserved, including proteins, 
GFs and cytokines. The preliminary step to evaluate successful DC is 
to use histological analyses to evaluate the sectioned DC tissue and 
look for nuclear and cellular residues, or lack thereof. Electron 
microscopy could be used to study the ultrastructure of the ECM before 
and after the DC process. These preliminary assessments of DC could 
then be followed up by more detailed analysis to evaluate the remaining 
ECM structure, its specific content of various components and/or other 
important scaffold attributes (several examples are summarized below). 
The DNA content in the ECM derived scaffold is very important since 
small and long strands of donor DNA remnants could cause an immune 
response after implantation. Smaller DNA strands can recruit (immune 
cells) as it signals apoptosis, while larger DNA strands could result in a 
foreign body reaction.148,149 Although the recommended threshold of 
acceptable remaining donor DNA in DC tissue is “less than 50ng of DNA 
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per mg of dry DC tissue”,130 that statement was made with no 
references and could merely be an arbitrary statement. This may very 
likely be tissue specific and needs further investigation. Another DNA 
criterion for DC tissue is that the remaining DNA fragments should be 
less than 200 base-pairs long, since such fragments may be degraded 
by the immune response post engraftment.150 
ECM proteins and GFs are important components in ECM derived 
scaffolds. The DC process should always strive to preserve these as 
much as possible. Hence, the remaining quantity of these constituents 
are often assessed in the DC tissue. The amount of collagen, elastin, 
GAGs, fibronectin, laminin and other ECM components are very 
important in order to achieve proper recellularization (RC) of the 
scaffolds. The amount of GFs that remain in the DC tissue also play a 
vital role as they promote seeded cells in downstream RC and 
transplantation applications.151 The most straightforward method to 
quantify GFs is by immunoassays. Although the most extensive method 
to determine every ECM component, including GFs, is by proteomics, 
it should be noted that GFs are denatured before the analysis and does 
not show if the detected GFs are functional.111,152,153 Nevertheless, there 
are assays that could demonstrate functionality of specific GFs 
responsible in regards to physiological activities such as 
neurogenesis154,155 and angiogenesis.156 
Mechanical properties of the scaffold are crucial physical attributes 
where the DC scaffolds need to have similar properties as the native 
tissue it should replace or repair. This is especially important in tissues 
submitted to mechanical stress such as blood vessels, esophagus and 
the uterus where the organ’s mechanical strength have to be retained 
in order to have functionality after engraftment. The mechanical 
strength can be measured using sheer-stress moduli, young’s modulus, 
expansion ratio, elastic modulus etc.111,157,158  
Sterility of the scaffold is, naturally, important if it ever will need to be 
recellularized and/or transplanted. Scaffolds produced by a DC process 
are usually sterilized by e.g. using the acidic-oxidizing per-acetic acid159 
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or by gamma radiation.160 However, both these methods can inflict 
significant damage to the ECM.161 
 
Recellularization 
The RC is the process of seeding cells to a DC scaffold with the goal to 
regenerate a functional construct that could repair or replace a 
damaged tissue in-vivo. The requisites for a successful RC are a well 
evaluated DC scaffold,130 a good cell source,162,163 a suitable cell culture 
media with GFs164 and a good cell culture environment in-vitro such as 




The cell source used for RC is an important consideration for the 
success of creating a functional bioengineered tissue. Optimally, the 
cell source should be from the patient to be transplanted to avoid a 
potential immune rejection event after transplantation. The cells should 
also be easy to obtain and be available in considerable quantities. It is 
further advantageous if the cells have a high proliferative potential, are 
easy to expand in-vitro and are safe to use for a clinical application. 
However, there are two general principles to consider that depends on 
the underlying purpose of the RC: a) the added cells are used with the 
aim to recreate and/or differentiate them into the specific tissue, or b) 
they are used to stimulate homing of endogenous stem cells and 
stimulate in-situ tissue regeneration by secreting paracrine factors after 
transplantation. Additionally, the choice of cells may also induce distinct 
immune response patterns.166 Broadly, there are two sources of cells, 
namely somatic cells and stem cells. 
Somatic cells 
Somatic cells specifically refer to the differentiated cells isolated from 
tissues of humans or animals. These cells have undergone a low 
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number of population doublings and therefore represent the source 
tissue more accurately as compared with a cell line that after many 
passages is adapted to an in-vitro milieu. The advantage of using 
somatic cells is the retention of functionality and the specific phenotype 
of the tissues or organs they are isolated from, making them the ideal 
cell type to use for reconstructing a specific tissue type. They are also 
better than using cell lines as immortalized cells may not be clinically 
approved because of a potential cancer risk, since the cells are 
manipulated to not lose their ability to proliferate (senescence). Somatic 
cells are easier to obtain compared with stem cells, and may be isolated 
from skin or from the endometrium. However, they are hard to isolate 
from organs such as the liver or the kidney without general anesthesia. 
Somatic cells also tend to stop growing after 40 to 60 population 
doublings. Unlike fibroblasts that grow very fast in-vitro, specific cell 
types such as epithelial cells or hepatocytes do not grow as fast and 
are also prone to rapid phenotypic changes.167 All these disadvantages 
suggest other cell sources should be investigated. 
Embryonic cells 
A zygote is a totipotent cell that can give rise to a whole organism while 
a pluripotent cell is a cell from the inner cell mass of a blastocyst that 
could differentiate into the three germ layers: ectoderm, endoderm and 
mesoderm. An embryonic pluripotent cell is more commonly known as 
an embryonic stem cell. These cells are generally derived from donated 
unused embryos created in abundance during an IVF treatment. The 
advantages with using embryonic stem cells for RC are the pluripotency 
which means that they could differentiate into almost any type of tissue. 
They are easy to obtain from IVF clinics with the right ethical approval 
and could rapidly be expanded to vast numbers in-vitro. The downside 
is risk of teratoma formation after transplantation,168 and the questions 
have been raised with respect to working with embryos for ethical 
and/or religious reasons.169,170 
Induced pluripotent stem cells 
Pluripotent cells can not only be obtained from zygotes but also from 
reprogrammed (induced) somatic cells by the introduction of the 
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Yamanaka transcription factors.171 Induced pluripotent stem cells have 
a main advantage of not causing an immune reaction when 
transplanted as they can be harvested and reprogrammed from cells 
taken from the recipient (autologous cells). They also have a high 
proliferative capacity that can be cultured to billions of cells from a 
relatively small starting cell number. This makes them an attractive cell 
source for RC in various TE studies. Additionally, they have the 
potential to differentiate into any cell type. As with their embryonic 
counter source, they can potentially cause teratomas after 
transplantation. However, with recent advancements, developed 
differentiation protocols can reprogram these pluripotent cells into a 
specific lineage, thus making them safer to use.172 Interestingly, a small 
part of the human population considered to be “super donors” could 
donate to a large part of the population, is elaborated later in this 
chapter.173 The induced pluripotent stem cells have been used to RC 
rat lung tissue where human cells attached and proliferated similar to a 
human lung environment.174 They were also used to RC liver scaffolds 
where a hepatic phenotype was stimulated using a 3D 
microenvironment of ECM derived scaffolds.175 
Multipotent stem cells 
Multipotent stem cells are progenitor cells that are more mature than 
pluripotent cells as described above. They have the ability to 
differentiate into a limited number of lineages. The two most commonly 
used multipotent stem cells are mesenchymal stromal/stem cells 
(MSCs) or adipose derived stromal/stem cells. Both these cell types are 
relatively easy to obtain and has the potential to differentiate into 
chondrogenic, osteogenic, adipogenic and myogenic lineages. The 
advantages of using these cells are the relatively easy isolation 
procedure, their basic culture requirements and the ability to be 
expanded in-vitro. These cell types have also been approved for clinical 
use and they have advantageous immunomodulatory effects and 
autologous characteristics when grafted. The downsides of using these 
cells are the inability to differentiate to any type of cell, and 
complications related to the isolation procedure such as harvest site 
infection. Furthermore, elderly patients have lower MSC population 
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reservoirs that may become inadequate for the cell numbers required 
for RC and organ reconstruction for this patient group.176-178 
 
Methods of recellularization 
The RC has been conducted using a multitude of methods in different 
milieu, from simple techniques that include injecting a very large 
number of cells into the organ following static cell culture conditions, to 
more sophisticated methods of administering cells through different 
organ/tissue specific conduits with the use of perfusion bioreactors. 
Each method used for RC can be successful, but much of it depends 
on the size and thickness of the tissue to be recellularized. 
Static recellularization methods 
Static RC is the standard RC method deployed by most studies that 
show a proof of concept of RC.179 The word “static” refers to that there 
is no agitation or perfusion during cell culture period directly after the 
cell seeding procedure. Rather, the RC scaffold is kept undisturbed in 
the incubator, usually submerged in cell culture media. This is usually 
also where the actual RC takes place by the administration of specific 
cells, commonly via direct injections using a syringe. Static conditions 
may not always result in a homogenous cell distribution, especially if 
the organ is thick or consists of a dense scaffolding structure. This may 
lead to apoptosis in the middle of the construct due to limited nutrient 
diffusion and an accumulation of toxic metabolites.180 Depending on cell 
types used for RC, the static RC methods could be advantageous for 
certain stem cells that grow well under hypoxic conditions.109 Other 
improvements for static RC conditions may include the use of transwells 
(TW) to increase media access to the construct147 or the use of 
hydrogels to seal the cell injection site on the scaffold after the 
administration to decrease cell leakage.181 
Dynamic recellularization methods 
Dynamic RC methods involve some kind of physical force such as 
agitation, stirring or cell perfusion to improve nutritional and metabolite 
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exchange in the RC scaffold to enhance cell adhesion, migration and 
proliferation. A bioreactor is a perfusion machine that traditionally is 
used to keep an organ viable in cold temperature between donor and 
recipient in an organ transplantation setting.182 As the knowledge in the 
field expanded, bioreactors are now being considered for RC of whole 
or partial organs.180 Bioreactors are often custom made for specific 
organs. For RC of simpler organs such as blood vessel and cartilage, 
spinner flask bioreactors can be used successfully where, for example, 
the perfusion medium flows on the outside of the organ, while cells in 
the luminal space are fed with a different media under constant spinning 
from a stirrer.183 Highly vascularized organs like the liver, lungs, kidney 
and uterus require more complex bioreactors with inlets and outlets for 
the arteries and veins, respectively, with constant monitoring of the 
perfusion loop, the vascular resistance and temperature. Additionally, 
attention to a change in the perfusate concentration of oxygen, carbon 
dioxide, glucose, pH and lactate is also critical to maintain an optimal 
RC environment and reduce the buildup of detrimental metabolites 
during the process.81,165,184 These factors may to some degree be 
regulated by the basic components of cell culture media used for 
perfusion solution. Generally, culture medium consists of 
carbohydrates, amino acids, lipids, vitamins, trace metals and buffers, 
all of which are the underlying vital components.185 It is most of the time 
also supplemented with antibiotics to prevent contamination186 and 
serum, or with a serum replacement, to provide albumin, GFs and 
hormones.187 Osmolality is also a very important aspect to the perfusate 
since it affects cell homeostasis and edema. This may be specific to 
certain cell types, since they differentially depend on the amount of ions 
absorbed or released, specific to the organ of interest.188 Additionally, 
oxygenation of the medium is important so that enough oxygen can 
reach the deep layers of the RC scaffold. Synthetic oxygen carriers 
such as perfluorocarbons have been used in cell culture to improve the 
oxygen concentration dissolved in culture medium.189 These oxygen 
carriers was also used in the clinic as a blood substitute for 186 patients 
suggesting that they can be used safely in-vivo.190  Oxygen carriers 
were also studied to reduce ischemic damage, suggesting that they 
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may have a protective effect during cerebral ischemia by preventing the 
vasoconstriction.191 
Figure 4. Overview of decellularization and recellularization 
 
Evaluation of recellularization 
A straightforward and frequent method to visualize seeded cells after 
RC is through histological analysis and microscopy. However, if the DC 
is incomplete and new cells are added to the ECM scaffold, it is difficult 
to distinguish between residual donor cells and the seeded cells that 
were used for RC. It is therefore likely that many studies overestimated 
their RC efficiency. A solution to this can be to tag the cells used for RC 
with a fluorescent molecule (e.g. green fluorescent protein) that 
distinguish them from any potential donor cells left in the scaffold.112 
Qualitative analysis could help to identify if the cells are distributed 
homogenously, and quantitative analysis should be performed to 
evaluate the cell density in the scaffold in an unbiased manner. Electron 
microscopic analysis is a powerful tool to elucidate cell-ECM 
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interactions at the ultrastructural level.181 Immunoassays are effective 
methods to determine cell phenotype and could be coupled with other 
methods such as gene expression analysis to verify the finding.192 
Mechanical tests could be deployed to see if the physical properties 
may have improved after RC and to investigate if the construct is 
comparable with the native tissue. Another method, which is a very 
comprehensive strategy to evaluate RC, is to conduct proteomic and 
genomic analyses on the construct to determine very detailed 
characteristics of the scaffolds and the cells.193 
 
Immune response towards tissue engineered 
grafts 
Tissue engineered grafts are composite scaffolds that are generated by 
unique DC processes, different sterilization protocols and distinct RC 
strategies, all of which can trigger or modulate the immune response 
after engraftment.194 The uniqueness of each graft type makes it 
complicated to draw parallel conclusions between studies. However, 
after the implantation of a tissue engineered graft, a constructive 
remodeling generally occurs that is orchestrated by infiltrated host cells. 
This event takes place simultaneously to the biomaterial degradation (if 
a degradable scaffold is used). Both these events are correlated with 
successful long term outcomes.195 
 
Immunogenicity of decellularized grafts 
The DC process changes the ultrastructure of the tissue due to the 
effect of the various DC reagents used for the scaffold production. This 
exposes damage-associated molecular patterns (DAMPs) which are 
fragmented ECM molecules dislodged from e.g. heparan sulfate, 
hyaluronic acid and fibronectin, among others. Cellular components 
could also act as DAMPs, including nucleic acids, high mobility box 
group 1, heat shock proteins and S100 molecules. All these molecules 
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are known to be able to induce an immune response after engraftment 
via the activation of toll-like receptors and receptors for advanced 
glycation end products proteins.196-198 
Extracellular matrix based DAMPs 
It has been shown that chemotaxis of neutrophils and monocytes can 
be triggered by fragments of ECM molecules acting as DAMPs 
following engraftment. This includes collagen199, elastin200 and 
fibronectin.201 Cytokine and chemokine production along with dendritic 
cell maturation could be triggered by damaged hyaluronic acid 
molecules202,203 and fragmented heparan sulfate structures within the 
ECM.204 It was also documented that laminin-based DAMPs induced a 
matrix metalloproteinase (MMP) 9 release in leukocytes that could 
facilitate the chemotaxis for inflammatory cells. Although the 
physiological role of MMP-9 secretion from immune cells is not known, 
it is hypothesized that the production of MMP-9 aids in their 
infiltration.205 
Cell based DAMPs 
Cellular-based DAMPs are released from dead cells and could, for 
instance, be a result of the DC process. For example, high mobility 
group box 1 proteins are chromatin proteins released from dying cells 
that can induce cytokine expression in immune cells and macrophage 
activation.206 Heat shock proteins may result in a cytokine induction and 
a stimulation towards dendritic cell maturation.207,208 S100 proteins 
released into the ECM from cell lysis can also lead to increased cytokine 
expression and chemotaxis of immune cells.206 Furthermore, DNA 
fragments are well known DAMPs and are associated with dendritic cell 
maturation and macrophage activation.148 For these reasons, it is 
generally regarded that low quantities of DNA that could act as DAMPs 
in DC tissue is advantageous. A somewhat arbitrary amount of 50ng 
double stranded DNA per mg dry scaffold was stated in a highly cited 
review article has become the general norm for scaffolds created by 
DC. Surprisingly, this amount was mentioned without any data or 
reference to back it up.130 However, there is evidence suggesting that 
the fragment size is important from an immunological perspective. 
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Thus, it has been suggested that the size of residual DNA fragments 
should be less than 200 base pairs (bp) in size to avoid a detrimental 
immune reaction. This maximum size limit is correlated to when 
apoptotic cells break down their DNA in a controlled fashion to 
fragments around 180 bp, without causing a negative immune 
response.209 Albeit, even small DNA fragments as low as 24 bp could 
activate macrophages.210 One often overlooked cellular component is 
RNA remnants, likely because of its rapid degradation. However, it 
should nonetheless be considered as a potential DAMP. 
 
Immunogenicity of recellularized grafts 
The overall immunogenicity of RC constructs is largely unknown. 
Besides the broad variability of the various DC scaffolds, RC constructs 
have further added variables as a consequence of the RC method 
employed, and the type of cells used. Very few studies investigated the 
immune response affected by the different types of RC methods. 
Nonetheless, there are some reports that assessed the immune 
response towards various type of cells commonly used in TE as 
summarized by Ochando et al.166 
Immunogenicity of embryonic stem cells 
The undifferentiated pluripotent nature of human embryonic stem cells 
may be regarded as non-immunogenic as a result of not inducing a T-
cell response, despite being allogeneic.211 Yet, in mouse models, 
allogeneic embryonic stem cells were rejected, an event that evolved 
faster following repeated administrations, possibly due to 
immunological memory mechanisms.212 Major histocompatibility factor 
(MHC) class 1 expression is relatively low in embryonic stem cells, yet 
somehow, it does not seem to trigger natural killer (NK) cells.213 
However, due to the potential allogeneic nature, these cells would 
require the administration of immunosuppression after engraftment. 
Therefore, it may be an advantage to find an alternative cell source for 
RC and TE applications. 
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Immunogenicity of induced pluripotent stem cells 
To overcome disadvantages incurred by the allogenic nature of 
embryonic cells, induced pluripotent stem cells could be used as they 
may be isolated from the prospective recipient, and thus, would be of 
autologous origin. Still, the process of creating induced pluripotent stem 
cells from cellular reprogramming may lead to epigenetic changes that 
risk unpredictable phenotypic variations. The MHC class 1 expression 
levels are generally low as a result from the reprogramming 
procedure.214 However, one downside with using these cells for TE is 
the cost and logistics required for the isolation and expansion process 
which would have to be repeated for every single patient in need of a 
personalized TE organ/tissue. More recent advancements have 
discovered that some donors are human leukocyte antigen 
homozygous, more popularly called “super donors”. As mentioned in an 
earlier in this chapter, cells isolated from such donors could be 
reprogrammed into induced pluripotent stem cells and used as a source 
for a significant number of potential recipients. It is estimated that 140 
of such “super donors” could cover about 90% of the world’s 
population.173 
Immunogenicity of adult multipotent stem cells 
Adult/tissue-specific stem cells have been used in TE on a multitude of 
organs over the last three decades.215 The scientists working with adult 
cells have been studying the properties of the cells in terms of 
differentiation ability. Yet, the immunogenicity is still largely unknown. It 
is known that hepatic stem cells can help with the reconstruction of 
livers, possibly because of the spontaneous regenerative ability of the 
liver and its constituent cells.216 They are also shown to reduce an 
inflammatory response by suppressing dendritic cell maturation, NK cell 
activity and T-cell proliferation by releasing prostaglandin E2.217 
However, the complete proliferative ability of adult stem cells from other 
organs may not be as good as the liver. In case of patients with a 
diseased or absent organ that is in need of a therapeutic tissue 
engineered construct, it would be difficult (or impossible) to isolate 
tissue-specific stem cells for this application. 
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Multipotent MSCs are considered to have a great advantage over many 
other cell sources for their accessibility and rapid in-vitro cell expansion 
characteristics. The increased use of MSCs in the clinic have shown 
that autologous and allogenic sources are safe to use and that they act 
immunomodulatory after transplantation.218 They have also shown to 
induce an immune-tolerance for tissue engineered constructs.219 
Nevertheless, the molecular patterns of the MSCs depend on the 
source tissue from which the cells are isolated from.220 With regards to 
uterus TE applications, MSCs are a promising source of cells for RC 
since a patient in need of a uterus transplant is likely to lack a native 
uterus to harvest cells from. 
 
Uterus tissue engineering 
Initial uterus TE studies mainly concentrated on the endometrium to 
investigate the effects of hormones and/or to study interactions 
between different uterus cell types in co-cultures. Most of the studies 
were performed using collagen matrix, sometimes with the addition of 
Matrigel. More specifically, these studies were performed in-vitro using 
cells from the rat,221 the rabbit222 and human.223-227  
 
Uterus tissue engineering in rodent models 
Recently, uterus TE has been studied more intensely and included the 
use of DC scaffolds to reconstruct uterine defects. Below is a brief 
summary of the most relevant published articles for this thesis, and a 
more extensive summary of uterus TE is detailed by Hellström et al.228 
, and by Campo et al.229 
Santoso et al. published a study in 2014 where DC uterine tissue 
segments from rats were analyzed.118 They compared three different 
DC protocols with 1) SDS, or 2) Triton X-100, or 3) high hydrostatic 
pressure. They concluded that protocols 1 and 3 were better than 
protocol 2. Therefore, when they conducted the in-vivo experiments 
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they only used these two uterus scaffold types. The full thickness 15mm 
⨯ 5mm DC scaffolds were repopulated with host uterine cells after 
engraftment. Pregnancy tests performed 30 days after engraftment 
revealed that the scaffolds were able to provide structural support 
during fetal development.  
The TE of whole rat uterus was first reported in 2014 by our group111 
and a group in Japan.116 Hellström et al. optimized three DC protocols 
for whole rat uterus, where the first two protocols were based on Triton 
X-100 and DMSO, dissolved either in deionized water or in phosphate 
buffered saline (PBS). The third protocol used the ionic detergent SDC. 
All the scaffolds were characterized for remaining ECM proteins and 
the scaffolds mechanical properties.111 This DC study was then followed 
up with a further investigation of RC and transplantation. Uterine 
patches (10mm ⨯ 5mm) were RC with fluorescently labeled MSCs 
together with primary uterus cells and were then transplanted to replace 
a full-thickness uterine wall injury.112 The fertility rates were restored in 
grafts from two of the three protocols when tested 6 weeks after 
engraftment. Hence, the Triton X-100 and DMSO protocols were better 
than the SDC protocol. Miyazaki and Maruyama tested an SDS based 
protocol that had previously been optimized for the liver.116 The DC 
whole uteri were recellularized with neonatal- and adult uterine cells 
and MSCs and then placed them in a perfusion bioreactor. Following 
that, uterine patches were cut out from the RC uterus scaffold and were 
transplanted in a similar way as described in the Hellström et al., study. 
This report also assessed functionality trough pregnancy tests 
conducted 28 days after engraftment. The number of fetuses in the 
grafted uterine horns were significantly lesser than in normal pregnant 
animals. However, the fetuses developed normally in the transplanted 
horns. This study was followed up by another transplantation study 
using DC uterine patches generated from the same SDS protocol but 
without any cells.115 This study revealed that the orientation of the ECM 
during transplantation is important to achieve the correct morphology 
during uterus regeneration and potentially result in uterine structural 
disease. However, when pregnancy tests were conducted on these 
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animals, properly oriented and disoriented grafts had the same number 
of fetuses growing in the operated horns. 
A similar process of TE was performed in a murine study, where DC 
uterus segments were grafted to the uterus of either ovariectomized 
mice or STAT3 conditional knockout mice. The results indicated that 
the regeneration process was not dependent on the ovarian hormones 
but showed STAT3 playing an important role.113 Nonetheless, these 
studies need to be further investigated to understand the mechanisms 
and also need to be evaluated again before scaling up to larger animal 
models. 
 
Uterus tissue engineering in lagomorph models 
Uterine TE was also reported in a rabbit model.230 In this study, non-
synchronous (i.e. a non-proliferative endometrium) and synchronous 
uteri (after ovarian stimulation) were DC using a combination protocol 
based on SDS, Triton X-100 and DNase. The assessment of DC 
showed the successful cell removal and a reduction in the total protein 
content. The DC endometrium was then isolated using microdissection 
and was further solubilized into a hydrogel. This ECM endometrium-
specific hydrogel was thoroughly characterized using proteomic 
analysis with respect of the two different hydrogels form synchronous 
and non-synchronous endometrium. Results showed that there were 
different quantities of ECM proteins such as collagen type III, collagen 
type IV and laminin among many others. The study concluded that 
synchronous endometrial hydrogel supported rabbit embryo 
development in-vitro better than hydrogels form non-synchronous 
endometrium, suggesting that donor hormonal stimulation prior to 
uterus DC procedure may be beneficial. 
The more recent study on uterus TE using a rabbit model describes the 
use of a biodegradable PGA/PLGA polymer based scaffold.97 Although, 
this study does not use DC tissue as scaffold type, and thus is outside 
the main scope of this thesis, it is worth mentioning since it shows the 
best regenerative results following a TE uterus patch replacement to 
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date. In this study, the authors seeded the polymer based scaffold with 
endometrial and myometrial cells. Seeded constructs, and unseeded 
scaffolds, (6-8 cm ⨯ 2.5 cm) were transplanted to replace almost the 
entire uterus horn, leaving only a long strand of the native uterus for the 
attachment of the long U-shaped graft. Six months of follow-up showed 
that the seeded constructs had regenerated and that they contained 
cells positively stained for the uterus-specific cell markers estrogen 
receptor alpha and progesterone receptor. Pregnancy tests in grafted 
animals also demonstrated that the seeded constructs had normal 
pregnancies inside the graft site with the fetus body weights 
comparable to the controls. One major drawback of this study is that 
the authors failed to clearly demonstrate the site of embryo implantation 
and placentation, and it seems like these key events took place in the 
native (i.e. normal uterus) tissue that was kept during the TE 
engraftment. Another downside with this study is that the choice of 
using parametric statistical analysis for a sample size of 3 animals in 
each group. 
 
Uterus tissue engineering in porcine models 
In the only uterus TE study performed on the pig, to my knowledge, is 
Campo et al. from 2017.109 The DC of the whole pig uterus was 
performed by vascular perfusion using an SDS and Triton X-100 
protocol. Histology after DC showed no detectable cells while retaining 
essential ECM components such as collagen, elastin, fibronectin, 
laminin and GAGs. Quantifications of remnant DNA and protein content 
showed a marked reduction compared with the normal tissue control. 
The RC of 5mm punched biopsies with human stromal- and epithelial 
endometrial cells resulted in scaffolds rolling up into organoid like 
structures suggesting the possibility to create human like tissue using a 
scaffold from a xenogenic source. 
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Uterus tissue engineering in ovine models 
There are two articles that have been published using the sheep animal 
model for uterus TE110,231 and one manuscript submitted (Padma et al., 
under revision; Paper III herein). Daryabari et al., reported successful 
DC of whole sheep uterus using three protocols based on: (i) SDS and 
Triton X-100, (ii) DMSO and Triton X-100 and (iii) SDS and formalin. 
Histological analysis of the DC scaffolds revealed successful removal 
of DNA while simultaneously remained positive for collagen, elastin, 
fibronectin, laminin and GAGs (in all three protocols). Toxicity tests 
showed that scaffolds generated by all three DC protocols were non-
toxic. Interestingly, the authors selected the DC scaffolds from SDS and 
formalin as being the best, and used these for a transplantation study 
into rats, despite it being a xenograft. The authors detected infiltrated 
cells on day 10 post transplantation. The cells within the grafts were 
stained positive for smooth muscle actin, cluster of differentiation (CD) 
31, Ki-67 and vimentin and the authors conclude this as sings of 
functionality, angiogenesis, cell proliferation and fibro-connective 
tissue, respectively.  
The other article on sheep uterus TE is Paper II231 which together with 
a submitted manuscript (Paper III) is presented later in this thesis.  
 
Uterus tissue engineering using human tissue 
Two studies that investigated TE of human uterus tissue. In the first 
study, DC rat and human myometrium were produced using ethanol, 
water and trypsin.232 These scaffolds were then RC with various rat and 
human monocyte cell lines where they cultured the constructs for up to 
51 days in-vitro. Interestingly, the human cells adapted better to rat 
scaffolds where multicellular layers were formed within the depths of 
the scaffold. They also showed contractility in organ bath experiments, 
indicating a potential functionality. In the other study, the authors 
performed DC on 1-2cm2 of endometrium layers of 0.5mm thickness 
using Triton X-100 and SDC with the aid of agitation.179 They 
characterized the DC scaffolds and confirmed low DNA levels and a 
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retained ECM morphology. Additionally, the authors recellularized the 
scaffolds and cultured the constructs for up to 4 weeks, and then 
followed it up by a hormone cycle treatment for 28 days. The cells 
responded and were positive for both estrogen receptor and 
progesterone receptors indicating the presence of a uterus specific cell 
phenotype. With this small elaboration of the principles of TE and 
current advancements in the field of uterus bioengineering, the parts 
about my contribution to the field is mentioned from the next chapter. 
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Table 1. A summary of uterus TE studies reported until February 2021.  
#The authors micro-dissected the endometrium and made into a hydrogel for downstream analysis. 
¤The authors called infiltration of cells after transplantation of DC scaffolds as RC 
Species Scaffold 
DC RC Grafting Pregnancy Reference 
















Yes SDS No N/A N/A N/A Yes 
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No N/A N/A N/A Paper III 
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AIM 
The overall aims of the thesis were: 
1. To investigate if the immune response towards 
decellularized uterus tissue was any different depending 
on what DC protocol was used in rats 
 
2. To scale up the uterus decellularization process from 
the rat to the sheep model and establish a successful 
protocol for a large organ 
 
3. To improve the recellularization efficiency of sheep 
uterus scaffolds 
 
4. To optimize and establish conditions that can keep a 
uterus viable ex-vivo in a perfusion bioreactor that may 
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MATERIALS AND METHODS 
This chapter includes a brief description of the materials and methods 
used in the experiments for this thesis project. A more detailed 
description of the methods is outlined in each paper at the end of this 
thesis (Papers I-IV). 
 
Study protocols for animal work (Papers I-IV) 
The study protocols for Paper I and III followed the guidelines detailed 
in the animal ethics applications for rodents which was approved by the 
Animal Welfare committee at the University of Gothenburg, Sweden 
(114-2014 and 6878-2019). Papers II and IV did not require specifically 
approved animal ethics protocols since the sheep organs used came 
from a local abattoir for food production. 
 
Animal work (Papers I-IV) 
Rat uterus (Paper I) 
For Paper I, 42 Female inbred Lewis rats and 3 outbred Sprague 
Dawley (SD) rats (Rattus norvegicus domestica) were used, all of which 
were 8-10 weeks old and between 140-180g in weight. Of these, twelve 
Lewis rats and three SD rats were used as donors. The remaining thirty 
Lewis rats were divided into five groups with six rats in each group. 
Group 1 received autologous grafts from their own uterus while group 
2 received allogenic uterus grafts from SD rat donors. Groups 3, 4 and 
5 received DC Lewis uterus tissue grafts that were developed from 
protocol (P) 1, P2 or P3 respectively. 
Uterus procurement 
The donor uteri used in Paper I for uterus scaffold production were 
isolated with an intact vasculature from the aorta to the vena cava to 
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enable whole organ DC through vascular perfusion. All vascular 
branches that did not lead to the uterus were ligated and cut. The 
specific uterus isolation procedures are detailed in an earlier publication 
and is summarized in Figure 5.117 
 
Figure 5. Figure used with permission from the publisher and authors.117 A 
diagrammatic representation of the vascular anatomy of the rat uterus where 
the ligations are represented by black bars. 1=abdominal aorta; 2=vena cava; 
3=renal vessels; 4= left renal vein; 5=left renal artery; 6=right renal vessels; 
7=lumbar vessels; 8=inferior (caudal) mesenteric artery; 9=common iliac 
vessels; 10=caudal vessels; 11=external iliac vessels; 12=internal iliac 
vessels; 13=superior gluteal vessels; 14=umbilical vessels; 15=inferior 
vesical vessels; 16=superior vesical vessels; 17=uterine vessels; 18=external 
pudendal vessels; 19=inferior epigastric vessels; 20=ureter; 21=urinary 
bladder; 22=recto-sigmoid colon (Rt., right side; Lt. left side).  
 
Rat embryonic dorsal root ganglion isolation (Paper 
III) 
Two time-mated SD rats were deeply anesthetized and embryos (aged 
embryonic day 14) were collected and placed in L15 dissection media 
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and used for the dorsal root ganglion (DRG) assay elaborated later in 
this chapter.  
 
Sheep uterus (Papers II-IV) 
A total of 149 sheep uteri were isolated from female Swedish Finull or 
Texel breeds of sheep (Ovis aries) for Papers II, III and IV. More 
specifically, Papers II and III used a total of 121 sheep uteri isolated 
from 8-24 months old sheep. From these, 32 uteri of similar size were 
randomly selected for the following groups, with 8 uteri in each group: 
control, P1, P2 and P3. Meanwhile, Paper IV used 28 uteri from 9-12 
months old sheep that were divided into four experimental groups, with 
each group receiving 7 uteri.  
Uterus procurement 
The uteri for Papers II, III and IV were obtained after a lethal trauma to 
the head that was followed by exsanguination according to standard 
culling protocols at the abattoir. Each uterus was dissected free from 
the surrounding tissue and cannulated through the uterine arteries. The 
cannulated uterus was then flushed until all the blood had been 
removed and until the specimen blanched using either ice-cold PBS 
supplemented with lidocaine and heparin (Papers II and III), or with ice-
cold Institute George Lopez-1 (IGL-1) solution supplemented with 
lidocaine and heparin (Paper IV). Each uterus was then submerged in 
flushing solution and kept on ice during transport to the laboratory. 
 
Decellularization 
Rat uterus (Paper I) 
The rat uterus DC procedure employed for Paper I has been elaborated 
extensively in earlier publications.111,117 In short, P1 and P2 were DC 
with 4% DMSO and 1% Triton-X100 for 4h, respectively, followed by 
16h of washing with PBS (P1) or deionized water (DW; P2). Protocol 3 
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was based on 2% SDC for 6h followed by 18h of washing with DW. The 
24h cycles were repeated five times after which the scaffolds were 
sterilized by the perfusion of 0.1% per-acetic acid in normal saline for 
30 minutes. Each uterus was then washed with sterile PBS and stored 
in -80°C until further used analyzed. 
 
Sheep uterus (Papers II and III) 
The DC process for the sheep uteri used in Papers II and III were 
performed in a custom-made perfusion DC setup. Briefly, P1 and P2 
were perfused with 0.5% SDS or 2% SDC for 8h, respectively. This was 
then followed by the perfusion of DW for 16h. Protocol 3 was based on 
a combination of a 2% SDC solution (which was perfused for 4h 
followed by a washing step with DW for 8h) and a 1% Triton-X100 
solution that was perfused for 12h. The procedure for P3 was repeated 
twice. The organs were then further perfused with DW to remove 
remnant detergents, this was followed by the perfusion of Dulbecco’s 
PBS (DPBS) to saturate the tissue with a buffer to enable the perfusion 
of a DNase 1 solution (40IU/mL) at 37°C for 1h. After the enzymatic 
treatment, DW was perfused for 48h to wash the organ further. All the 
uteri were sterilized with the same method; the perfusion of 0.1% per-
acetic acid for 1h. The sterilization liquid was then washed away with 
the perfusion of sterile PBS for 48h. The DC organs were then frozen 
at -80°C. Biopsies were taken for microscopy and quantitative analysis 
after thawing. For Paper II, the analysis of the DC sheep uterus tissue 
were conducted on cut ring sections with a thickness of 0.3-0.5cm. For 
Paper III, the DC uterus tissue was thawed and uterus scaffolds were 
made with a biopsy punch to create DC uterus tissue discs (dUTDs) 
5mm in diameter comprising all the uterus layers (full-thickness of the 
uterus). 
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Bioreactor (Paper IV) 
Figure 6. A schematic diagram of the perfusion bioreactor system used in 
Paper IV 
For Paper IV, a customized cell culture medium was used as perfusion 
solution in the bioreactor. The perfusion medium composition had been 
optimized with different GFs and synthetic oxygen carriers individually, 
and then in various combinations using explants of sheep uterus rings. 
Two groups were used to study any cold ischemia induced detrimental 
effects on the uterus between the uterus isolation time and the 
normothermic reperfusion event started in the bioreactor (4h and 48h). 
The isolated sheep uteri exposed to the two alternative organ 
preservation times were connected to the Hugo Sachs electronics 
perfusion bioreactor system comprising a moist chamber, heat 
exchanger, oxygenator, media reservoir, pressure meter and a 
peristaltic pump (Figure 6). The media and all gas-filled spaces of the 
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bioreactor was enriched with carbogen gas (95% O2 and 5% CO2). A 
total of 250mL of recirculating perfusion medium for every organ was 
used and the arterial perfusion pressure maintained below 60mmHg 
(8kPa). Each organ perfusion group was compared to a control group 
where the uteri were instead kept in preservation solution at at +4°C. 
Biopsies and media samples were taken every 12h for histology and 
biochemical analysis, respectively. 
 
Grafting surgery (Paper I) 
The DC rat uteri used in Paper I were thawed from long-term storage, 
cut into 10⨯5mm pieces and sterilized with gamma irradiation. Three 
grafts per animal were transplanted subcutaneously to each rat under 
isoflurane anesthesia to assess a potential activated immune response 
caused by the grafts. The five experimental animal groups consisted of; 
1) autologous grafts, 2) allografts, 3-5) sterile DC uterus grafts from 
each DC protocol, respectively. Each patch was secured to the 
underlying tissue with 6:0 polypropylene sutures and the wound was 
then closed using 4:0 silk sutures. The rats injected with an analgesic 
cocktail of carprofen and buprenorphine to reduce pain and 
inflammation. One biopsy from each grafted rat was retrieved at day 5, 
15 and 30, respectively, and used for histological and gene expression 
analyses (see below) targeting recruited immune cells and pro-
inflammatory cytokines.  
 
Toxicity tests (Paper II) 
For Paper II, a toxicity test was used to study if there were any cytotoxic 
remnant DC reagents in the scaffolds after the DC process using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
This assay is based on the ability of metabolically active cells to convert 
MTT dye to the insoluble formazan crystals through the NAPD cycle. 
Any toxic compounds present in the culturing medium would affect the 
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metabolic activity of cells, and thus, toxicity correlates with lower 
formazan amount which is measured by spectrophotometry. In Paper 
II, the storage solution that the DC uteri had been kept in was included 
into the medium used to culture a standard cell culturing cell line 
(human embryonic kidney 293 cell cultures) along with the MTT dye.  
 
Bioactivity tests (Paper III) 
In Paper III, the functionality of remaining GFs in the scaffold after the 
DC process was evaluated using two different bioactivity tests: 
The DRG assay: Isolated DRGs were placed on to either collagen 
coated wells or on the endometrial side of the dUTDs. The axonal 
regeneration of the cultured DRGs were assessed after two days and 
analyzed with immunohistochemistry. 
The chicken chorioallontoic membrane (CAM) assay: The angiogenic 
activity of DC sheep uterus tissue was assessed using fertilized chicken 
eggs. A small window was opened in the shell of each egg on embryo 
development day (EDD) 3 and the shell opening was then closed using 
a patch of Tegaderm. On EDD 9, the shell window was reopened and 
an alginate hydrogel drop (control) or a DC uterus disc was inserted on 
the CAM (experimental groups represented each scaffold type). The 
egg was further incubated to EDD 14, and then the blood vessels that 
grew towards the insert were counted under an operating microscope 
to assess if the dUTDs simulated angiogenesis. 
 
Mechanical tests (Paper II) 
The mechanical strengths of native and DC sheep uteri were measured 
in Paper II since the physical properties of a scaffold used in 
bioengineering applications determine the fate of grafted cells, and 
have a major role in its degradation characteristics. For this, biopsies 
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were cut from the uterine horns and placed in a sheer stress modulus 
testing machine, where the force required to pull the tissues apart was 
measured. The maximum load (N/mm), tensile strength (J/mm), the 
amount of extension needed (%) and the sheer/stress modulus (Pa) 
were determined for each scaffold type and for the native uterus ring 
samples.  
 
Fetal stem cell isolation (Papers II and III) 
To isolate a cell population that could be advantageous for the RC of 
DC sheep uterus tissue and future sheep uterus bioengineering, 
heterogeneous sheep fetal bone marrow stem cells (SF-SCs) were 
isolated from 6-8 week old sheep fetus. The fetuses were obtained from 
pregnant sheep culled for food production. They were isolated from the 
uterus, dissected to expose their femur bones which were opened in 
both ends. The bone marrow was flushed out using Leibovitz L-15 
medium. The bone marrow was collected in a tube and was cleaned by 
multiple centrifugation steps and was then plated out in a petri dish and 
cultured under standard cell culturing conditions. The cells were 
characterized and used for the RC procedures thoroughly explained in 
Papers II and III.  
 
Recellularization (Papers II and III) 
The DC sheep uterus tissue from all three protocols were recellularized 
in Papers II & III. More specifically, in both papers, the RC procedure 
was carried out in standard cell culturing conditions. However, further 
experiments were conducted in Paper III to improve the RC efficiency 
by using an enzymatic pre-treatment of the scaffolds before the cell 
seeding procedures. Additional improvements in RC were conducted 
by using TW inserts during cell culture (see below). All the RC scaffolds 
were analyzed using immunohistochemistry and microscopic analyses. 
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Recellularization under standard conditions 
In Paper II, sectioned rings of DC sheep uterus tissues were 
recellularized with either 1⨯106 or 10⨯106 SF-SCs using a syringe and 
multiple sequential injections. Since there was no benefit using the 
higher concentration of cells, the lower concentration was used in Paper 
III. This study used the 5mm dUTDs (instead of the ring-shaped 
scaffolds used in Paper II) and was RC with the endometrial side up 
using the same cell application approach as in Paper II. The RC 
efficiency was assessed after standard cell culturing conditions for three 
days or for 14 days in-vitro. 
Recellularization in transwells  
In Paper III, with the intent to improve the RC efficiency by increasing 
the cell culture medium access to the myometrium side of the RC 
dUTDs (bottom), each construct was placed on a 0.4μm pore sized TW 
insert during cell culture. The dUTDs were recellularized with multiple 
injections the same way as mentioned above. The RC efficiency was 
again assessed after three days or 14 days in-vitro. 
Recellularization after enzymatic preconditioning and 
transwell culture 
An additional RC experimental group was included in Paper III. In this 
group, the dUTDs were enzymatically pre-treated for 24h with MMP 2 
and 9 before being placed in the TW inserts, then they were 
recellularized and cultured as the other scaffold types before the RC 
efficiency was assessed. 
 
Microscopic analyses (Papers I-IV) 
In Papers I-IV, all the biopsies retrieved were fixed in either 
formaldehyde or glutaraldehyde for histology or electron microscopy, 
respectively. The biopsies were dehydrated and processed for the 
respective microscopic analysis mentioned below. 
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Histochemistry (Papers I-IV) 
Hematoxylin and eosin (H&E) staining was performed in all Papers. 
Slides stained with H&E was also used to quantify the total number of 
cells per mm2 (using ImageJ) in Paper I and for the microscopic 
measurements to quantify tissue edema in Paper IV. Additional 
standard staining protocols were used in Paper II to evaluate the 
morphology for ECM components before and after DC. These included 
Masson’s trichrome (MT) stain, Verhoeff van Geison (VVG) stain and 
Alcian Blue (AB) stain to detect collagen, elastin and GAGs, 
respectively. 
 
Immunohistochemistry (Papers I-IV) 
To visualize DNA in processed tissue, sections were stained with 4′,6-
diamidino-2-phenylindole (DAPI) in Papers II, III and IV. Additionally, 
quantification of DAPI positive cells were used in Paper III to assess the 
RC efficiency, and was used in Paper IV to quantify tissue edema after 
normothermic bioreactor reperfusion of sheep uterus after they had 
been exposed to cold ischemia. 
Bright-field immunohistochemistry of stained immune cells using 
antibodies for CD4 (T-cells), CD8a (cytotoxic T-cells), CD22 (B-cells), 
CD68 (macrophages), CD163 (activated macrophages) and natural 
cytotoxicity triggering receptor 1 (NK cells) Immuno-labelled positive 
cells were stained red with the Mach 3 kit and facilitated quantification 
of the specific cell types presented in the results for Paper I. Similarly, 
positive cells stained for cleaved caspase-3 were quantified in Paper IV 
to evaluate cold ischemia and reperfusion-induced apoptosis in the 
sheep uterus. 
Immunofluorescent staining was performed in Paper II and III to 
characterize the phenotype of the SF-SCs used for the RC process, 
including the markers α-smooth muscle actin, vimentin, CD166, Ki67, 
estrogen receptor-α, estrogen receptor- β, progesterone receptor, 
cytokeratin, myoblast determination protein 1, receptor activator of 
Arvind M Padma 
51 
nuclear factor κ B and dentin matrix acidic phosphoprotein 1 before and 
after the RC procedure. Additional immunofluorescent staining was 
conducted in the DRG assay using a pan-neurofilament antibody to 
label regenerating axons. 
 
Scanning electron microscopy (Papers II and III) 
Scanning electron microscopy was performed on normal, DC and RC 
sheep uterus tissue and is presented in Papers II and III. To enable the 
visualization in the scanning electron microscope and to improve the 
contrast in content DC samples due to its low lipid content, each 
specimen was processed using the osmium tetroxide and 
thiocarbohydrazide (OTOTO) method.233 
 
Biochemical analysis (Paper IV) 
The components of the customized cell culture medium used as 
bioreactor perfusion solution for Paper IV were analyzed using a blood-
gas system specifically measuring concentrations of sodium, 
potassium, glucose, pH and lactate. These factors provided relevant 
indicators for tissue/organ health during the bioreactor experiment. 
 
DNA, RNA, protein and ECM quantification 
(Paper I and II) 
Gene expression analysis was conducted in Paper I by isolating total 
RNA from tissue biopsies taken from the grafts at specific time-points 
after uterus scaffold transplantation. The RNA from these biopsies was 
then quantified by spectrophotometry, then converted to cDNA which 
was quantified in a droplet digital polymerase chain reaction (ddPCR; 
see below). In Paper II, DNA samples were isolated, quantified and 
loaded on an agarose gel to evaluate the size of remaining DNA after 
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the various DC protocols. This was conducted since large fragments of 
remaining DNA may affect the immunogenic properties of the scaffolds. 
Additionally, in Paper II, total protein and ECM components such as 
collagen, elastin and GAGs were isolated and quantified using 
optimized commercial colorimetric assay kits for respective 
components. 
 
Gene expression analysis (Paper I) 
All the procedures for ddPCR in Paper I followed the internationally 
established dMIQE guidelines for this type of work.234 The isolated RNA 
was reverse transcribed to complimentary DNA using standard 
molecular kit-based methods after which the ddPCR were performed. 
In brief, each sample along with the master mix were divided into 
16,000-20,000 individual droplets where the PCR reactions occur 
individually in each droplet. The PCR positive droplets get a “1” value 
and the negative droplets get a “0” value (hence, it is called digital) and 
the copies/μL was calculated using Poisson’s mathematics. The 
specific expression levels that were analyzed this way included the pro-
inflammatory cytokines interferon-γ, interleukin (IL)-1β, IL-2, IL-6 and 
tumor necrosis factor. 
 
Statistical analyses (Papers I-IV) 
Statistical analysis for Papers I-IV were performed using Graphpad 
Prism. All data were tested for normal distribution with the Shapiro-Wilk 
test. When data sets were normally distributed, two group analysis was 
performed using the unpaired two-tailed Welch’s t-test, and multiple 
group analysis was performed using one-way ANOVA with Tukey’s 
HSD post-hoc analysis for multiple group corrections. For data with a 
skewed distribution (non-parametric), two group analysis was 
performed using the two-tailed Mann-Whitney U test, and multiple 
group analysis was performed with Kruskal-Wallis multiple group 
comparison corrected with Dunn’s post-hoc analysis. The data sets 
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were plotted either as bar graphs (mean ± standard error of mean), box 
plots (median, interquartile range and range) or line graphs (mean ± 
standard error of mean). 
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In short, however, Paper I investigated if the process of DC affects the 
immunogenicity of the scaffold. ECM derived scaffolds should not 
provoke a strong immune response after transplantation since ECM 
molecules have a close molecular homology between species. 
However, the DC process and its chemicals may expose DAMPs that 
potentially could induce a detrimental immunological reaction after 
engraftment, even in a syngeneic transplantation setting. Hence, this 
needed to be investigated. Cells in biopsies isolated from transplanted 
syngeneic rats that received DC uterus tissue were quantified, and on 
day five after transplantation, the total infiltration of cells were 
significantly higher for P1 scaffolds compared with P2 and P3 scaffolds. 
The density of resident T-cells were significantly higher in P3 scaffolds 
compared with autologous grafts (control group). The cytokine 
expression levels of IL-1β was higher in P1 and P3 scaffolds, while IL-
2 was elevated in P3 scaffolds. Fifteen days after transplantation, P3 
grafts had an increased presence of cytotoxic T-cells, and the B-cell 
population had decreased in P1 and P2 scaffolds. The IL-1β expression 
remained higher in P3 derived scaffolds compared with the other 
groups. Thirty days after transplantation, there was no difference in any 
immune cell numbers that we analyzed, while IL-1β expression levels 
remained at a higher level in P3 scaffolds compared with the other 
grafts.  
Overall, the immune response after the transplantation of the three 
different types of ECM derived uterus scaffolds had an early and a late 
immune response that were allogenic-independent. This suggests that 
DAMPs were formed during the DC process. The results indicated that 
the DC protocol that used mild detergent (P2) but was still effective in 
reducing the donor DNA content contained lower amounts of DAMPs 
and resulted in a moderate immune response, while an aggressive DC 
protocol (P3) seemed to have generated more DAMPs that triggered a 
stronger immune response. 
Tissue engineering for novel female infertility treatments 
56 
Paper II 
Macroscopic observations of the perfused sheep uterus revealed 
successful cannulation and organ procurement since the plastic replica 
model of the whole uterus vascular network were intact. The uteri 
blanched in color and turned white as the DC process progressed for 
all DC protocols (P1-P3). Microscopic analysis of the DC sheep uterus 
displayed the absence of cells (based on H&E stained slides), while the 
architecture of collagen, elastin and GAGs was retained (evident by the 
MT, VVG and AB staining, respectively). Scanning electron microscopy 
further demonstrated that the ECM ultrastructure contained intact 
collagen fibers and that it left a porous ECM structure with no visible 
cell structures present. 
Quantification of the scaffold components presented a significant 
decrease of DNA content in all scaffolds compared with normal tissue. 
The remaining DNA fragment size were less than 500bp. The amount 
of total protein content and GAGs also decreased significantly 
compared with normal uterus tissue. Simultaneously, the amount of 
collagen decreased significantly in P1 and P3 scaffolds, while the 
elastin content significantly decreased in P2 and P3 scaffolds. 
Mechanical tests showed an increase for the maximum load in DC 
tissue after all three protocols, while the work required to destroy the 
samples remained unchanged in P1 and P2 scaffolds. The elasticity of 
the samples was increased in P1 scaffolds while P2 and P3 derived 
scaffolds remained closer in elasticity to the normal uterus. 
All three DC scaffolds were found non-cytotoxic based on the MTT 
assay. There were viable cells near the injection sites in all RC scaffold 
types after 14 days in-vitro. However, it was obvious that the cells 
remained near the injection site and did not migrate much during the in-
vitro period. This was irrespective of the DC protocol used. Interestingly, 
there was no difference in the RC efficiency when the constructs were 
seeded with 1 or 10 million cells. However, when taking all the results 
into consideration, P2 seemed to generate the best type of uterus 
scaffold compared with P1 or P3, since it had similar collagen content 
and mechanical properties to the native tissue. 
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Paper III 
The experiments of Paper IV explored the scaffolds used in Paper II 
further and the RC strategies were further optimized. The study also 
looked into any potential functional bioactivity of the GFs in the DC 
scaffolds. More specifically, the DRG assay showed that dUTDs 
stimulated the DRGs to regenerate an increased amount of axons that 
grew longer distances compared with the control group, thereby 
demonstrating the existence of bioactive GFs that stimulated 
neurogenesis. In the CAM assay, the dUTDs resulted in a doubling of 
blood vessels in the vicinity of the scaffold, thereby demonstrating that 
the uterus scaffolds contained bioactive GFs that stimulated 
angiogenesis.  
The RC of the scaffolds using standard culturing conditions showed that 
there was an increased ability for cell proliferation in P1 and P2 
compared with P3 scaffolds. Using TW inserts during the cell culture 
increased the cell density in P1 and P2 scaffolds compared with P3 
scaffolds short term, but did not seem to have a significant beneficial 
effect long term. Enzymatically pre-treated scaffolds that were cultured 
in TW inserts showed an increase in the RC efficiency in all three 
scaffolds, both in short and long term, compared with standard 
conditions. Interestingly, the pre-treatment of the scaffolds improved the 
RC efficiency even for P3 derived scaffolds which now became 
comparable with P1 and P2 scaffolds in cell density. In summary, pre-
treatment of the DC scaffolds with MMPs prior to the RC process 
improved the RC efficiency and resulted in a 2 to 3 times increase in 
cell density compared with standard cell culturing conditions, 
independent of DC protocol used. 
 
Paper IV 
In paper IV, a perfusion bioreactor system was optimized and used for 
assessing cold ischemia and reperfusion damage of the normal sheep 
uterus. This experiment was conducted not only for its relevance to UTx 
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research, but also to optimize future whole sheep uterus scaffold RC 
experiments where such sophisticated 3D in-vitro culture system may 
prove beneficial.  
Analysis of H&E stained slides revealed that the outer serosa layer and 
the inner columnar luminal epithelial cells was affected by edema during 
the normothermic reperfusion in the bioreactor, regardless of the 
duration of the cold ischemia. However, Group 1 with the shorter cold 
ischemia time did not show any increased edema in the endometrial 
layer while the uteri exposed to the longer ischemia time (Group 2) 
showed a significant swelling of this layer. This significant edema was 
also accompanied by an increased apoptosis that progressed with the 
duration of the reperfusion, something that was not seen in Group 1. 
The columnar epithelium in the lumen was affected in both groups as 
the normothermic reperfusion time progressed. However, this was a 
much more rapid process in the group previously exposed to the long 
cold ischemia time (Group 2) where the epithelium had completely 
disappeared after just 24h of reperfusion. 
Biochemical analysis of the perfusate taken from regular intervals 
during the perfusion time revealed that the glucose concentration 
significantly decreased in later time points in both groups and that the 
pH significantly decreased over time only in Group 2. Lactate levels 
became elevated after 24h of uterus reperfusion in Groups 1 and after 
36h in Group 2. The potassium levels were significantly increased in 
Group 2, but not in Group 1 that had the short initial cold ischemia time 
exposure. To sum up the general results for Paper IV, as expected, we 
saw a clear difference in organ quality depending on the exposure time 
of cold ischemia during the reperfusion event. The detailed differences 
observed using the reperfusion platform showed that the bioreactor 
may very well replace the need for large animal UTx experiments to 
study different cold ischemia and uterus preservation protocols to 
optimize UTx protocols. Additionally, this bioreactor system may 
similarly be used for uterus TE experiments where large uterus scaffold 
RC can take place in a controlled 3D in-vitro perfusion culturing system.  
 




In Paper I, three different rat uterus scaffolds with a varying degree of 
remaining fragmented donor DNA were evaluated after transplantation 
in a syngeneic rat animal model. P1 scaffolds, which had the highest 
amount of donor DNA remnants as a result from the gentler DC 
protocol, caused a higher infiltration of cells during the first five days 
after engraftment. It is likely that this was caused by the higher presence 
of the nucleotide based DAMPs in this scaffold type compared with the 
other scaffolds evaluated. However, the total cell density in P1 grafts 
was reduced over time, suggesting a scaffold clearance from DMAPs 
and a potential path towards remodulation.235 
Lymphocytes are normally recruited to the graft as a consequence of 
both the innate and the adaptive immune response. However, neither 
the density of CD4+ T-helper cells nor the CD8a+ cytotoxic T-cells were 
any different in the control groups or in P1 and P2 scaffold grafts, 
suggesting an absence of a negative immune response.236,237 But the 
number of cytotoxic T-cells were higher in P3 grafts, indicating a 
potential presence of ECM-based DAMPs, which correlated with a 
higher CD22+ B-cell population in this group 15 days post engraftment. 
Hence, the higher presence of both cytotoxic T-cells and B-cells in P3 
may indicate that there was a progression towards rejection or 
unfavorable tissue regeneration in this graft type. Both T-cells and B-
cells have shown to contribute to transplantation tolerance or mediate 
graft rejection by and induced cytotoxic response.204,238 Additionally, 
macrophages can be involved in either rejection or wound healing 
depending on its activation and the proportions of the different 
macrophage phenotypes. The infiltrated CD68+ pan macrophages and 
the infiltrated CD163+ class M2 macrophages were not significantly 
different in any of the time points between the protocols. Although, 
transplantation of TE urinary bladder and small intestinal submucosa 
resulted in a higher anti-inflammatory (M2) macrophages,239 we did not 
make similar observations. We also did not detect elevated levels of IL-
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6, IFN-γ and TNF-α, that are related to higher pro-inflammatory (M1) 
macrophage presence.240,241 M1 macrophages can stimulate 
angiogenesis through the M1-dependent VEGF signaling pathway and 
have been associated with degrading implants.194 Hence, the low M2 
macrophage density detected in this study may be due to a slow 
scaffold degradation. Additional studies would be need to validate these 
hypotheses, and further investigate the whole immunological response 
towards DC scaffolds. These studies should include anti-inflammatory 
signals (e.g. IL-1, IL-4, IL-10) on the protein level (serum analysis) and 
the mRNA level (ddPCR) using larger grafts transplanted orthotopically. 
To create the best possible scaffold, it is crucial to have an optimized 
uterus DC protocol that produces a minimal amount of DAMPs so that 
the scaffold can favor regeneration and tissue reconstruction. The 
clarification of optimal protocols to accomplish this will enable the 
translation of these bioengineering principles to larger animal models, 
and finally to the human.  
In summary, the study of Paper I investigated the existence of allo-
independent immunogenic DAMPs in uterus scaffolds generated from 
three DC protocols. We clearly demonstrated that one scaffold type (P2; 
produced by a mild DC protocol) did not seem to induce a detrimental 
immune response after engraftment. 
 
Paper II 
To scale up uterus TE protocols from a small to a large animal model is 
a challenging process, including choosing a relevant large animal 
model. Ribitsch et al. described in detail the advantages and 
disadvantages of using different animals for translational research.242 
For the uterus, the closest animal model to a human is a non-human 
primate model (e.g. macaque or the baboon model). However, it is 
difficult to obtain ethical approval for such experiments and it is also 
very expensive to work with these animals. Thus, we instead chose the 
sheep model. The sheep uterus has a close resemblance to the human 
uterus in terms of general size and morphology. Additionally, the sheep 
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rarely has more than two fetuses during pregnancy, while the pig model 
is considerably different to the human uterus.243 However, there are 
some significant differences between the sheep and the human uterus 
that needs to be considered for translational work. For instance, 
invasive placentation that takes place during fetal implantation in 
humans is different to the sheep that instead is dependent on multiple 
smaller cotyledons-dependent placentae.244 Additionally, the genetics 
of the sheep is often mixed to benefit food and fur production which 
consequently result in a relatively high heterogeneity between animals 
that can complicate research conclusions. However the sheep organs 
used in Papers II-IV came from a local slaughterhouse and provided us 
with a near unlimited supply of uteri that otherwise would have been 
discarded. In line with European animal welfare regulations, no 
requirement for an ethical permit was needed, thus, providing us with 
many advantages using this animal model. However, future 
transplantation studies will have to include exorbitant costs to cover 
housing and animal care during. 
At the beginning of the sheep uterus DC study (Paper II), we conducted 
a pilot study to evaluate if the best protocol established on the rat (Paper 
I; P2; 1% Triton-X100 + 4% DMSO), could DC the sheep uterus. 
However, this protocol was found ineffective. Interestingly, this was 
contradicting to what Dayabari et al. concluded.110 They used a similar 
protocol to P2 in Paper I, but they also used formalin in combination 
with this protocol for the sterilization process. The use of formalin is 
debatable, since, through its fixation process it severely impacts the 
ECM crosslinking. The consequences for this ECM crosslinking is not 
well documented and may result in unfavorable RC conditions and/or 
problematic outcomes following transplantation. 
Our three different protocols for sheep uterus DC described in Paper II 
showed that there were protocol-dependent differences in scaffold 
composition with respect to collagen, GAGs, elastin amounts. The 
mechanical properties were also significantly affected by the choice of 
DC protocol used. Microscopic analysis and the quantifications 
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revealed that P2 that were based on SDC had a potential advantage 
over the other protocols.  
The DNA quantities were minuscule in all three protocols suggesting 
that all these scaffold types should harbor a low immunogenicity caused 
by donor DNA. However, the GAGs content was also decreased in all 
protocols. This is a common consequence from the DC process caused 
by the combination of ionic detergents. GAGs are water soluble, thus 
making them even harder to maintain during perfusion-based DC 
protocols.125 But this reduction could be overcome by supplementing or 
pre-treating the scaffolds with solubilized GAGs before any downstream 
RC process245 which creates new ideas for future applications with the 
developed sheep uterus scaffolds.  
Together with the MTT test, the developed uterus scaffolds’ RC ability 
confirmed that the scaffolds were non-cytotoxic. Injected cells were 
predominantly found in the periphery of the uterine rings and were 
concentrated around the injection site. The observed limited distribution 
of cells after RC may be caused by a suboptimal cell injection 
procedure, and/or by a compact scaffold structure that negate cell 
migration.  However, it may also be caused by remnant DC chemicals 
that was not properly extracted from the deeper tissue layers during the 
washing steps, plausibly causing a central cytotoxicity in some regions 
of the scaffolds. Better cell migration and a higher cell turnover should 
be beneficial for transplantation studies, hence, exploring this further 
and improve the RC efficiency would be of great value before future 
transplantations studies. 
Overall, we observed that the rat uterus DC protocol needed to be 
modified in order to establish good sheep uterus scaffolds. Our results 
also showed that a uterus the size of a human uterus can be 
decellularized successfully. The developed P2 (the SDC-based 
protocol) seemed to be more favorable compared to the other evaluated 
protocols. Since this protocol also used a relatively mild detergent 
treatment, it may also contain less DAMPs, and thus, be more favorable 
after engraftment (Padma et al.; Paper I). 
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Paper III 
The natural progression after establishing successful DC protocols of 
sheep uteri (Paper II) was to improve the RC strategies (Paper III). 
Efficient RC is not only dependent on how the cells are added to the 
scaffold and how the constructs then are cultured, but is also dependent 
on scaffold GF content. Since GFs support such an event, an 
abundance of studies quantifying different GFs in DC scaffolds were 
conducted.111,230,246 However, the quantification methods used are 
based on denatured proteins. Thus, the results from these studies do 
not demonstrate GF functionality. Functional GFs are crucial to facilitate 
the seeded stem cell migration and proliferation, and to facilitate 
reconstruction after implantation and angiogenesis.247 
Two bioactivity tests were performed in Paper III to assess scaffold 
bioactivity and the presence of functional GFs: the DRG and the CAM 
assays (neurogenesis and angiogenesis, respectively). It was evident 
from the DRG assay that all three dUTDs induced axonal growth and 
that the axons grew longer compared with the collagen substrate 
control group. This indicated that there was a presence of neurogenic 
GFs. This method however, did not discriminate specific GFs 
responsible for different parts of neuronal sprouting.248 There are 
cytokines such as IL-6 that are responsible for tissue regeneration, 
including for uterus tissue,113 which also are known to play a role in 
growth of DRGs.154 Nonetheless, the exact mechanism needs to be 
further investigated in order to improve regeneration post implantation 
of the constructs.  The CAM assay confirmed angiogenic properties of 
the dUTDs. More specifically, a near doubling of blood vessels were 
formed around the dUTDs compared with the control group. Angiogenic 
GF remnants in the scaffolds could be advantageous after engraftment 
as it would reduce the ischemia after transplantation. However, 
additional studies need to be done in order to determine if the effects 
are caused by functional GFs or by inherent properties of the scaffolds. 
This is an interesting area for further research that could include setting 
up similar assays but with the addition of specific GF inhibitors in the 
cell culture medium to determine growth-dependent signaling pathways 
(e.g. VEGF, STAT3 or IL6).113,154 
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Recellularization is a demanding feat and few studies have actually 
shown high cell densities in ECM scaffolds that were quantified in an 
unbiased manner and compared with native tissue. Furthermore, many 
studies used constructs that were grafted after a relatively short time in-
vitro after the RC process. Additional heterogeneity between TE studies 
include method for cell delivery,181 time cultured in-vitro after RC249 and 
by what type of construct culture system used (e.g. static cell culture, a 
bioreactor system or culture spinner flasks).184,250 The choice of cell type 
used for the RC also plays an important role. These variables make 
studies difficult to compare. We used heterogeneous multipotent SF-
SCs for our RC experiments in Paper II and III. They demonstrated 
multipotency before and after RC, thereby indicating that the cells did 
not differentiate in-vitro when cultured with the sheep uterus scaffolds. 
Similar cell types have been established to produce GFs and ECM 
components that are especially responsible for tissue regeneration,251 
activate repair mechanisms,218 and a similar cell type have shown to 
play a beneficial role in endometrial repair following cell transplantation 
to the uterine spiral arteries in a clinical setting.252 
The previous study (Paper II), and most other studies commonly use 
the strategy described as “standard culturing condition” in Paper III.  As 
observed in other studies, this method resulted in a limited RC 
efficiency with a sparse cell aggregation concentrated around the 
injection sites and not clear indications of cell migration towards the 
deeper scaffold structures.109,112,231 When the scaffolds were RC and 
cultured on TWs, the cell density improved compared with standard 
culturing conditions. The cells also migrated further from the injection 
site which are similar observations to what was documented in another 
study on kidney RC.147 
The physical properties such as porosity of the scaffolds can affect the 
RC efficiency.253,254 With this in mind, we pre-treated the scaffolds with 
MMP-2 and MMP-9 that are widely expressed by proliferative and 
migrating cells that use these enzymes to breakdown the ECM 
components to ease their mobility251,255 and accelerate angiogenesis.256 
When the scaffolds were treated with MMPs and then RC and cultured 
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in TWs, there was a considerable advantage seen already on day 3, 
and an even more pronounced benefit noted after 14 days in culture. 
Even the least efficient scaffold (P3) became comparable to the other 
two scaffold types with regards to cell density and migration. The cells 
clearly migrated better and proliferated more in the scaffolds after the 
MMP treatment irrespective of the DC protocol used for scaffold 
generation. 
In essence, this study displayed bioactivity in DC uterus scaffolds that 
stimulated neurogenesis and angiogenesis. The MMP preconditioning 
of scaffolds before RC and TW culture improved the cell density by 
200%-300% compared with standard culture conditions, irrespective of 
DC protocol used for scaffold production. Additional studies may 
include optimizing the cell seeding procedure further, e.g. using circular 
multi-needle injectors instead of repeated single injections, prolonged 
in-vitro periods for RC constructs (e.g. 1-2 months) and the RC of larger 
scaffolds.  Furthermore, the administration and efficacy of the MMP 
preconditioning treatment needs to be tested on whole organ RC to 
evaluate if this can potentially be combined with the use of perfusion 
bioreactors for successful RC of large constructs and future 
transplantation studies on the sheep uterus. 
 
Paper IV 
An extracorporeal perfusion bioreactor is commonly used to preserve 
or recondition an organ before organ transplantation in the clinical 
setting.182,257 This is usually conducted below 4°C. However, Recent 
organ preservation studies indicated that a normothermic 
extracorporeal organ perfusion setup using a blood based perfustate 
exhibited milder organ damage after transplantation compared with 
standard cold storage procedures for the liver258 and kidney.257 
Similar strategies might be used for whole organ RC applications in TE. 
However, whole organ RC in a perfusion bioreactor is challenging and 
requires constant monitoring of a multitude of variables, including 
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medium composition (e.g. glucose, pH, lactate and osmolality), oxygen 
saturation, vascular pressure and edema prevention. 
In order to establish some base line criteria and facilitate for future 
whole organ RC experiments on the sheep uterus scaffolds created in 
Paper II, we designed a normothermic perfusion platform for the sheep 
uterus in Paper IV. This perfusion platform was also relevant for 
studying uterus ischemia and reperfusion induced injury, which is still 
not a well characterized area. In the clinic, the uterus is not an essential 
organ for transplantation. Therefore, it is likely that other organs will 
have priority from a multi-organ donor during procurement. This may 
lead to longer cold ischemia times compared with the easier logistically 
planned living donor procedures that can allow shorter ischemia times. 
For example, the cold ischemia time for the first successful UTx that 
used a deceased donor was 6.5h69 while the cold ischemia time for the 
succesful live donor UTx cases was about 1.5h.259 
Our perfusion system used a peristaltic pump to circulate the perfusate. 
Since this can cause hemolysis of red blood cells,260,261 we developed 
a perfusion solution containing perfluorocarbons as synthetic oxygen 
carriers to substitute the red blood cells. These oxygen carriers have 
successfully been used in the clinic intravenously to elevate saturated 
oxygen levels in the blood190 and reduced cerebral ischemic damage 
and demonstrated non-toxicity.191 We also added reactive oxygen 
species scavengers to counteract potential detrimental effects from 
reactive oxygen species released during the reperfusion.85  
Many clinical and pre-clinical studies on organ preservation use 
standard solutions like Perfadex, Histidine-Tryptophan-Ketoglutarate, 
University of Wisconsin, IGL-1 or Steen solution, all of which contain 
high levels of either polyethylene glycol, mannitol or albumin to reduce 
edema formation. These also contain low (or no glucose) to decrease 
the metabolic activity in cold temperature perfusion systems. As a 
result, the lactate levels are respectively low under such settings. 
However, in Paper IV, the perfusion was performed at normothermic 
temperatures (37°C). Therefore, when the perfusate was analyzed after 
the perfusion of the sheep uterus at different time-points, the lactate 
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levels had increased while the pH decreased. These parameters are 
explained by the recirculation of the perfusion medium for 48h and the 
high metabolic activity in the organ. These metabolites may be 
detrimental for the organ and better results may have been obtained if 
the perfusion medium was not recirculated, or if the media was replaced 
at regular intervals.  
However, when the organs were histologically analyzed, a low degree 
of apoptosis was seen in the group exposed to a short ischemia time. 
These are good results considering that we performed the 
normothermic perfusion for 48h in the bioreactor. We observed more 
cleaved caspase-3 positive apoptotic cells in the group exposed to 48h 
of cold ischemia. This ischemic-related damage was expected since 
such duration is considerably long, and far from optimal for organ 
transplantation.  
The system may be optimized further, for example if the maintenance 
of the osmolality during the perfusion was kept at about 300mOsm/L.262 
The luminal epithelial layer in both groups degraded during the 
perfusion which may have been caused by changes in osmolality during 
the experiment.263 Additionally, the edema observed after prolonged 
reperfusion in both groups could potentially be dampened by increasing 
the albumin or polyethylene glycol concentrations and/or lower the 
solute concentration. 
From a UTx perspective, we were able to discriminate differences in 
cold ischemia-related injuries using this developed normothermic 
perfusion system, and we demonstrated that these bioreactor settings 
could act as a substitute for expensive in-vivo experiments to assess 
the reperfusion injury. Hence, this system could be used to evaluate 
different types of cold preservation solutions for uterus procurement at 
a much lower cost and effort than using live animals for transplantation 
studies. Additionally, we established base line criteria for the medium 
composition and perfusion bioreactor settings. These important 
parameters will assist us to develop whole organ RC protocols for future 
uterus bioengineering applications on large organs. 
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CONCLUSIONS 
Paper I The immunogenicity of the scaffolds was DC protocol 
dependent, and the remaining donor DNA also played 
an important role. The rat uterus scaffolds generated 
from P2 that used a milder decellularization protocol 
contained fewer DAMPs and was better than the 
scaffolds produced by a more aggressive detergent. 
Therefore, P2 scaffolds should be the focus for future 
uterus TE studies on the rat model. 
Paper II To scale up DC protocols from the rat to the sheep model 
warrants the establishment of new DC protocols. The 
sheep uterus scaffolds produced by an SDC-based 
protocol seem to be the best among the developed 
protocols as it retained the ECM morphology better and 
resulted in scaffolds with comparable mechanical 
strength to the native sheep uterus. 
Paper III All the decellularized sheep uterus had functional 
bioactive GF that stimulated neurogenesis and 
angiogenesis. Preconditioning of the scaffolds prior to 
RC using MMPs, and culturing the constructs in TW 
inserts increased cell density by 200-300% compared 
with normal RC and culturing strategies, independent of 
protocol used for decellularization. 
Paper IV We developed a perfusion bioreactor system that could 
maintain sheep uteri viable ex-vivo for 48h where cold 
ischemia-related injuries could be assessed after 
reperfusion. Hence this platform could be used to assess 
different novel preservation solutions for uterus tissue to 
improve UTx protocols. These perfusion parameters 
also serve as an excellent baseline to develop novel RC 
protocols for whole sheep uterus bioengineering. 
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